WO1996002661A1 - Process for producing protein capable of molecular weight reduction caused by protease of host-cell origin - Google Patents
Process for producing protein capable of molecular weight reduction caused by protease of host-cell origin Download PDFInfo
- Publication number
- WO1996002661A1 WO1996002661A1 PCT/JP1995/001399 JP9501399W WO9602661A1 WO 1996002661 A1 WO1996002661 A1 WO 1996002661A1 JP 9501399 W JP9501399 W JP 9501399W WO 9602661 A1 WO9602661 A1 WO 9602661A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein
- medium
- host cell
- molecular weight
- column chromatography
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6456—Plasminogen activators
- C12N9/6462—Plasminogen activators u-Plasminogen activator (3.4.21.73), i.e. urokinase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21073—Serine endopeptidases (3.4.21) u-Plasminogen activator (3.4.21.73), i.e. urokinase
Definitions
- the present invention relates to a method for stably producing a large amount of an unstable protein which can be reduced in molecular weight by a protease derived from a host cell.
- host cells that produce and secrete the protein obtained by genetic manipulation are cultured in a medium containing a specific substance to enhance the growth of the host cells and promote the production and secretion of the protein
- the present invention relates to a method for mass-producing a protein that can be reduced in molecular weight by a host cell-derived lipase by suppressing the reduction in molecular weight.
- tissue t-PA produced by vascular endothelial cells
- perokinase UK
- perokinase when used in large quantities, has the drawback of inducing the degradation and activation of coagulation and fibrinolytic factors and inducing a tendency to bleed.
- blow mouth kinase an inactive precursor of human ostium kinase produced by human cells [hereinafter referred to as blow mouth kinase.
- Japanese Unexamined Patent Publication (Kokai) No. 60-62981 (EP-B-1 394 47), J. Biol. Chem .. 260, 12 377 (1985)] is a fiber constituting a thrombus. It has a specific affinity for fibrin, has thrombolytic properties such as the selective degradation of fibrin, and more preferably, the blow mouth kinase, unlike perokinase, causes a bleeding tendency. Cell Struc. Func .. 10, 151 (1985)] found no defect.
- blow mouth kinase having such excellent properties is expected to be widely used clinically as a fibrinolytic enzyme.
- Pichia pastoris which has an effect of increasing the secretion amount in the case of human serum albumin or invertase, as a host cell (Bio / Technology, 5, 1305-1308. 1985). Although the oral kinase was examined in the same manner, the secreted amount of the protein into the medium was lower than that of human serum albumin and the like, and considerable brourokinase remained in the cells without being secreted.
- the present inventors have found that when the Pichia yeast is cultured in a YPM medium, there are many degradants of about 47 kDa and about 30 kDa in addition to those of 5 O kDa which are considered to be intact proteins in the culture. I noticed that This 47 kDa protein was determined to be a deletion of the intact blow-mouth kinase N-terminus from the results of ⁇ -esten blotting with a monoclonal antibody recognizing the EGF domain (Evider-Malgro-factor). However, it was considered that the Blow-mouth kinase was reduced in molecular weight by proteases derived from host cells and the like present in the culture supernatant.
- the present invention relates to the production of a protein that can be reduced in molecular weight by a protease derived from a host cell by an enzymatic or genetic engineering technique, wherein the protein is reduced in molecular weight. It is an object of the present invention to provide a method for mass production without mass production. Specifically, a host cell-derived protein that can be degraded by a host cell-derived protease is added to the host cell. It is an object of the present invention to provide a method for producing a large S protein by stably producing and secreting a large amount of white matter and suppressing the low molecular weight after secretion.
- the recombinant host cell is at least one selected from acidic amino acids, basic amino acids, phosphates, ammonium salts and nonionic surfactants.
- the present invention relates to a host cell that secretes and produces a protein that can be reduced in molecular weight by a protease derived from a host cell, and more particularly, to a method for transforming Pichia yeast into an acidic amino acid, a basic amino acid, a phosphate, an ammonium salt, and a nonionic interface. Culturing in a medium containing at least one selected from the group consisting of activators, and collecting the protein from the resulting culture supernatant. How to make protein
- the present invention provides a method for collecting a protein which can be degraded by a protease derived from a host cell from a culture supernatant in the production method, the method comprising the steps of: using a buffer solution containing ammonium salt for column chromatography on a culture supernatant; A method for producing a protein that can be reduced in molecular weight with a host cell-derived protease, which comprises treating with a hydrophobic column chromatography and a cation exchange column chromatography, preferably.
- the present invention provides a transformant (Bikia yeast) that produces and secretes blow mouth kinase.
- FIG. 1 is a diagram showing a method of constructing the plasmids p K O 110, ⁇ ⁇ 1 113, and ⁇ ⁇ ⁇ 114.
- FIG. 2 shows a method for constructing plasmids pKO116 and pKO117. 0
- FIG. 3 is a diagram showing a method for constructing brassmid pKO122 and a blow-mouth kinase secretion expression vector ⁇ 126.
- FIG. 4 is a diagram showing a restriction enzyme map of the blow mouth kinase secretion expression vector pKO126.
- FIG. 5 is a graph showing the growth of Pichia yeast SC06 strain cultured in five types of methanol media in Experimental Example 1 over time.
- ⁇ Medium 1
- medium Medium 2
- ⁇ Medium 3
- X Medium 4
- ⁇ Medium 5
- FIG. 6 is a diagram showing the time course of the ⁇ activity in the culture supernatant obtained by culturing the Bikia yeast SC06 strain in five types of methanol media in Experimental Example 1.
- ⁇ Medium 1
- Medium 2
- ⁇ Medium 3
- X Medium 4
- ⁇ Medium 5
- FIG. 7 shows the results of a Western plot (electrophoresis) performed in Experimental Example 4.
- Lane 1 Using ⁇ medium
- Lane 2 YP 2 + 23 ⁇ 4NH 4 H 2 P0 4 + 23 ⁇ 4 (NH *) 2 HP0 4
- Lanes 3 and 4 ⁇ + 0.013 ⁇ 4 Tri-ton X-100 + 0.1M arginine lanes 5 and 6: ⁇ 2 ten 0.013 ⁇ 4 Tri-ton X-100 + 0.1M arginine
- host cell-derived protease refers to a protease encoded by a chromosome gene of a host cell.
- proteases are presently found in yeast in about 30 or more species, and are present in vacuoles (yscA, yscB, yscY), mitochondria (yscMpI), periplasm (ysdl) and the like.
- yscA, yscB, yscY mitochondria
- mitochondria yscMpI
- periplasm periplasm
- the protein targeted by the production method of the present invention is not particularly limited as long as it can be reduced in molecular weight by the action of the above-described host cell-derived protease.
- plow-mouth kinase human tissue plasminogen activator, blood coagulation factor IX, blood coagulation factor X, protein c, interferon, epidermal grosspha Kuta-1 (hereinafter referred to as EGF) and ⁇ -dolphin are exemplified.
- EGF epidermal grosspha Kuta-1
- ⁇ -dolphin is particularly preferred.
- the protein targeted by the present invention is not limited to a naturally-derived protein, and may be a mutant obtained by genetically mutating a natural protein or a derivative obtained by artificially modifying the natural protein.
- a mutant obtained by genetically mutating a natural protein or a derivative obtained by artificially modifying the natural protein For example, in the case of blow-mouth kinase, the entire region or part of the evidermal macroglobulin factor domain of the natural blow-mouth kinase is deleted, or the entire region or part thereof is S-replaced with another amino acid residue.
- blow-mouth kinase derivative in which the asparagine residue at position 302 from the N-terminus of the natural blow-mouth kinase is substituted with a glutamic acid residue, and an annexin having thrombus affinity at the C-terminal side of the natural blow-mouth kinase And a fusion protein to which V protein is bound (PCT International Publication No. WO 92/19279).
- These derivatives are sugar-free blow-mouth kinases to which no asparagine-linked sugar chain is added, and are expected to be applied as thrombolytic agents due to their high thrombus affinity.
- the host cell used in the present invention is not particularly limited as long as it can secrete and produce a protein that can be reduced in molecular weight by the above-mentioned protease, and it does not matter whether the host cell is naturally derived or obtained by gene manipulation. Absent. In addition to those already described in publicly known documents, those that will be developed in the future can be used as appropriate. Specifically, a bacterium having a function of expressing a gene encoding a protein that can be degraded by a host cell-derived protease in a cell, producing the protein, and secreting the protein outside the cell. , Escherichia coli, yeast, mold and Bacillus subtilis.
- Pichia pastoris Piichi na /) a5toris
- GTS 1 15 his 4
- Etc. NRRL accession number Y—1 585 1 Etc.
- a method for preparing a host cell capable of secreting and producing a protein that can be reduced in molecular weight by the above protease by a gene recombination operation can be carried out by employing a known method or a method analogous thereto.
- a method for preparing a host capable of producing and secreting blow mouth kinase a method described in JP-A-60-180591 (EP-B-154272) (Saccharomyces ⁇ ), a human tissue plasminogen activator
- JP-A-60-180591 EP-B-154272
- Sacharomyces ⁇ a human tissue plasminogen activator
- Examples of the method for producing a host that produces and secrete include the method described in Transfusion Medicine, p303-313. (1986).
- Pichia yeast When Pichia yeast is used as a host cell, it can be prepared by contacting the S gene of the target protein with a promoter of the AOX gene that is strongly induced by methanol in the medium according to a conventional method.
- both the autonomous propagation type and the chromosome integration type are used as the expression vector, but the expression vector is preferably the chromosome integration type. More preferably, the expression vector has the 5 'and 3' untranslated regions of the AOX gene at both ends, and is HIS4 which is one of the best candidates in addition to the AOX promoter, foreign gene and AOX terminator. It is a straight-type vector with a distant element.
- Transformation was performed by the spheroblast method (Cregg, JM et al., Mol. Cell. Biol .. 5.3376-3385, 1983), the alkali cation method (Ito, H .. et al., J. Bacterid .. 153, (1) 163). -168. 1983) can be used.
- a strain having histidine auxotrophy (his-) is preferably used as a host cell.
- his- histidine auxotrophy
- the production method of the present invention relates to a protein that can be reduced in molecular weight by a host cell-derived protease.
- Host cells capable of secreting and producing white matter are cultured in a medium containing at least one selected from the group consisting of acidic amino acids, basic amino acids, phosphates, ammonium salts, and nonionic surfactants.
- This makes it possible to obtain a large amount of a protein which can be reduced in molecular weight by a host cell-derived porcine protease from the culture supernatant in an intact state. That is, the culture method is considered to contribute to expression of the target protein in host cells, improvement of production efficiency, promotion of extracellular secretion, or suppression of low molecular weight by protease.
- Examples of the acidic amino acid used in the present invention include aspartic acid and glutamic acid, and examples of the basic amino acid include arginine and lysine. Preferably, it is arginine or glutamic acid.
- Acidic amino acids and basic amino acids may be used in the form of a salt. Examples include sodium aspartate, potassium aspartate, sodium glutamate, potassium glutamate, alginine hydrochloride, and lysine hydrochloride.
- amino acid content fi in the medium is usually about 0.02 to 0.5M, preferably about 0.05 to 0.3M, and more preferably about 0.1M.
- the phosphate used in the present invention include ammonium phosphate I NHJ HPO * or NH 4 H 2 PO «] and sodium phosphate [Na 2 HPO4 or
- the content of phosphate in the medium is about 2 to 5 w / v%, preferably about 4 w / v%.
- Anmoniumu salt used in the present invention phosphoric acid Anmoniu ⁇ [(NH) 2 HPO * or NH «H 2 PO4], Anmoniumu carbonate [(NH 4) 2 C0 3 or NH 4 HCO3], Anmoniumu chloride [ NH 4 Cl] and the like.
- the content of ammonium salt in the medium is about 2 to 5 wZv%, preferably about 4 wZv%.
- the phosphate or ammonium salt is preferably in the form of ammonium phosphate, more preferably in the form of a combination of (NH 4 ) 2 HPO * and NH 4 H 2 PO 4 .
- (NH *) 2 ⁇ 5w / v% is a 2 HPO * and NH 4 H 2 PO * content in total, and preferably about 4wZv 3 ⁇ 4.
- Li down ⁇ or Anmoniumu salts especially (NH 4) 2 HPO4 and ⁇ * ⁇ 2 ⁇ 0 by ⁇ the host cell of the present invention 4 in a medium containing, Protea is ⁇ secreted from the host cell Ichize
- nonionic surfactant used in the present invention examples include polyoxyethylene mono ⁇ -tert-butyl tert-butyl ether and polyoxyethylene sorbin fatty acid ester.
- the content of the nonionic surfactant in the medium is about 0.005 to 0.03 wZv%, preferably 0.01%.
- the medium used in the present invention may contain at least one selected from the group consisting of the above acidic amino acids, basic amino acids, phosphates, ammonium salts and nonionic surfactants.
- Arginine in Naka preferably contains Anmoniumu phosphate [(NHJaHPO * and NH4H 2 PO «] and 3-ton X- 1 00.
- the other components are not particularly limited as long as the medium used in the present invention fulfills the above conditions and can grow and proliferate the host cells.
- Other combinations Examples of the component include components contained in a known medium commonly used in this field.
- various sugars (glucose, glycerol, etc.) are generally used as carbon sources, urea and usate are used as nitrogen sources, various vitamins and nucleotides are used as sss nutrients, and inorganic salts such as Mg, Ca. Fe, Na, K , Mn, Co, Cu salts and the like.
- YNB liquid medium [0.7% amino acid-free yeast nitrogen base (manufactured by Difco), 2% glucose], YPD liquid medium [1 ⁇ yeast extract (manufactured by Diico), 2% bactopeptone (Difco) Co., Ltd., 2% glucose], etc.
- a methanol-containing medium can be used. Is about 0.01 to 5%, and specifically, a YPM medium [1% yeast extract, 2 pact peptone, 0.01 to 5% methanol] is exemplified.
- the medium used in the present invention is prepared by adding at least one selected from the above-mentioned acidic amino acids, basic amino acids, phosphates, ammonium salts and nonionic surfactants to a conventionally known medium. Can be easily prepared.
- the pH of the medium may be neutral, weakly basic or weakly acidic. It is preferably pH 6-8.
- the cultivation can be carried out by using the above-mentioned medium and appropriately selecting conditions under which the cells produce the maximum amount of the target protein and efficiently secrete it in a conventional manner.
- the culturing temperature is usually 15 to 43'C, preferably 20 to 3O'C, and the culturing time is usually about 1 to 1,000 hours. If necessary, it can be cultured under aeration.
- preculture Prior to the main culture, preculture can be performed under the same conditions.
- the target protein secreted into the culture supernatant can be collected from the culture by known separation and purification means.
- the culture is subjected to ultrafiltration or centrifugation to obtain a culture supernatant, and the culture supernatant is subjected to salt precipitation such as ammonium sulfate precipitation, gel-based treatment, treatment with an anion exchanger, cation Purification of the target protein by subjecting it to various treatments such as treatment with an exchanger and treatment with hydrophobic chromatography Can be.
- the target protein of the present invention is easily degraded by a protease derived from a host cell, it is preferable to purify the target protein from the culture by the following method.
- a culture solution containing ammonium salt is used in the initial stage of purification by a conventional method such as a centrifugal separation method or an ultrafiltration method. This is a method of treating by column chromatography under the condition of low protein S.
- the buffer used here is not particularly limited as long as it is a buffer containing an ammonium salt.
- it is a buffer having a buffering capacity in a neutral region (pH 6 to 8, preferably about pH 7), and the concentration of the contained ammonium salt is preferably 0.05 to 5 M.
- concentration of the contained ammonium salt is preferably 0.05 to 5 M.
- the present invention can effectively suppress the reduction of the molecular weight of the target protein by a protease, and can purify and obtain an intact protein in a high yield.
- Column chromatography includes ordinary protein purification such as anion exchange column chromatography, cation exchange column chromatography, gel permeation column chromatography, hydrophobic column chromatography, chelate resin column chromatography, etc.
- Column chromatography used for purification of proteins produced by gene engineering techniques is exemplified.
- a preferred embodiment of the present invention includes a combination of hydrophobic force column chromatography and positive ion exchange column chromatography.
- aqueous column chromatography and cations are preferably carried out using a buffer solution containing ammonium salt, more preferably using an ammonium phosphate buffer solution (pH 6 to 8).
- a method of performing exchange column chromatography By such a method, the target protein having high specific activity can be isolated at a high yield with a small amount of intact with a small amount of degraded product.
- the treatment by the hydrophobic chromatography used in the present invention can be performed according to a conventional method.
- hydrophobic chromatography carrier examples include an insoluble carrier having an alkyl group having 4 to 18 carbon atoms (such as a butyl group, an octyl group, and an octyldecyl group) or a phenyl group.
- Preferable examples include a fuunil base type, and specific examples include phenyl cellulose (trade name: phenyl cell mouth fine, manufactured by Seikagaku Corporation) and phenyl agarose (trade name: phenyl sepharose, manufactured by Pharmacia). Is exemplified. Adsorption and elution conditions can be appropriately selected according to the target protein to be purified.
- the contact conditions include pH 6 to about 8, preferably pH 7 and a salt concentration of about 0.5 to 1.5M, preferably about 0.5 to 0.8M.
- the elution conditions are about pH 6 to 8, preferably about pH 7, a salt concentration of about 0.05 to 0.7 M, preferably about 0.1 to 0.5 M, and more preferably about 0.2 M.
- the treatment by cation exchange chromatography can also be performed according to a conventional method.
- any insoluble carrier having an intestinal ion exchange group can be used.
- 3 ⁇ 4Examples of the ion exchange group include a carboxymethyl (CM) -based type and a sulfopropyl (SP) -based type. It is preferably an SP type, and specific examples include SP-agarose (trade name: S-Sepharose, manufactured by Pharmacia), SP-dextran (trade name: SP-Sephadex, manufactured by Pharmacia) and the like. You. Preferred conditions for adsorption and elution can be appropriately selected according to the target protein to be purified.
- the contact conditions include pH 6 to about 8, preferably pH 7 and salt odor of about 0.01 to 0.2M.
- the elution conditions include about pH 6 to 8, preferably about pH 7, and a salt concentration of about 1 to 1M.
- a protein that can be reduced in molecular weight by a protease produced by a genetic engineering technique or an enzymatic method can be produced in large form in large size in a complete state. That is, by culturing a host cell that secretes and expresses the protein in the medium referred to in the present invention, it enhances the expression of the host cell, improves the production S of the protein, and secretes the protein from the host cell. Is promoted. Further, according to the present invention, it is possible to effectively suppress the low molecular weight of the protein secreted into the culture medium.
- the nonionic surfactant used in the present invention does not directly contribute to the growth of host cells or the suppression of protein depolymerization, but has an effect of suppressing the disappearance of proteins by adsorption to instruments and the like.
- Amino acids especially arginine and glutamic acid, have the effect of increasing the growth of host cells and inhibiting the production of low-molecular-weight proteins.
- ammonium phosphate effectively suppresses the reduction of protein molecular weight.
- the growth of host cells and the production and secretion of proteins are synergistically improved.
- the unification method of the present invention it is possible to effectively suppress the decomposition of proteins that are liable to be reduced in molecular weight at the stage of production, and to efficiently purify and intact intact proteins in high yields. Further, the present invention can provide, for the first time, a Pichia yeast (transformant) capable of secretory production of a blow mouth kinase.
- NH 4 -PO * refers to ammonium phosphate buffer containing (H *) 2 HPC and thigh 4 H 2 PO4, and Na—P0 * refers to Na 2 HPO «and NaH 2 P 0 «. Means the contained sodium phosphate ⁇ city liquid.
- Plasmid JUKI (Hiramatsu et al., Gene. 99. 235-), an expression vector for Sacch ronyces cerevisiae containing a gene in which a signal sequence derived from the gene and the Blow Mouth Kinase cDNA are connected in frame. 241. 1991, JP-A-3-240493 and JP-A-4-166088) were partially digested with B1II and then digested with PstI to obtain a part of the signal sequence and A 330 bp fragment containing a portion of the oral kinase cDNA was isolated.
- T4 polynucleotide kinase and ATP are added to 5 jiig linkers a and b (Table 1) purified using an OPC column (Abride 'Biosystems Japan) and incubated at 37'C for 30 minutes. To phosphorylate the 5 'end.
- Linker a 5 ⁇ -TCGAGATGTTGTTCTCTAA-3 '
- Linker b 3'-CTACAACAAGAGATTCTAG-5 '
- linkers a and b were mixed and heated at 70 for 20 minutes, and then allowed to cool to room temperature.
- the annealed linker and 330 bp PstI-Bg1II fragment prepared from Brasmid JUK1 were mixed and ligated, followed by ethanol precipitation. ⁇ was performed to recover DNA.
- the precipitate was dissolved in TEClOmM Tris-HC1 (pH8.0), 1 mM EDTA], mixed with a PstI-Bg1II fragment, ligated, and ethanol precipitated S to recover DNA. .
- the precipitate was dissolved in TE, and digested with PstI-XhoI to isolate a 36-Obp fragment.
- This fragment was ligated with a 2.7 kb Pstl-XhoI fragment prepared from pKO110 and then introduced into Escherichia coli for transformation.
- Brasmid was isolated from 39 clones of ampicillinous colonies.
- Primary screening by restriction enzyme digestion was carried out to select 6 clones of plasmid, and the nucleotide sequence in the vicinity of the introduced linker was examined with a liquid phase sequencer Quensa-1 (Pharmacia). The sequence was as expected (sequence listing, SEQ ID NO: 2).
- Two clones were selected and named pKO I13 and pKO114 (3.05 kb) (Fig. 1). Mucor.
- Brasmid N302Q is aspartic acid, the 302th amino acid from the N-terminus of the brass-mouth kinase cDNA of Brasmid JUKI. Codon AAT of glutamine to CAG of glutamine, site-specific mutagenesis method (Molecular Cloning, A Laboratory Manual. Second edition. Sambrook. J. et al., 1989, modified by Cold Spring Harbor Laboratory, New York), in which the asparagine-linked glycosylation site has disappeared.
- pKO116 was digested with BamHI and ⁇ I to separate a 3.95 kb DNA fragment.
- p SV—G 1 -UK which is an expression vector for mammalian cells containing blow mouth kinase cDNA (see Japanese Patent Application Laid-Open No. 63-105675 (EP-A-2656784)).
- a 320 bp DNA fragment was obtained by digestion with BamHI and KpnI, ligated to a PKO116 DNA fragment (3.95 kb), and excised pKO 118 was obtained.
- ⁇ 118 was digested with ⁇ I, blunt-ended with ⁇ 4DN ⁇ volimerase, and then added with pXhoI linker (Takara Shuzo).
- the 1.57 kb fragment was separated by XhoI digestion and cloned into the XhoI site of pKO110 to obtain the plasmid pK0121.
- PK0121 was digested with XhoI to isolate a 1.57 kb DNA fragment, which was cloned into the XhoI site of pA0807NX.
- PKO126 was isolated with the insert inserted in the forward direction ( Figures 3 and 4).
- ⁇ pAO807Nx is a cloning site for plasmid pHIL-D2 (Invitrogen) Ec This is a plasmid in which the oR I recognition site has been converted to an Xhol recognition site (Esco R I digestion of the plasmid pH IL-D2, fill-in with Klenow fragment, addition of pXho I linker, and then Xho I digested fragments were ligated and ligation reaction was performed to prepare pAO80707NX).
- PKO126 (1Oiig) obtained in Example 1 was digested with zymorylacese, and treated with calcium chloride to make it a competent Pichia yeast iPichia pastoris GTS 115: NRRL deposit number Y—15851)
- HI S + transformant was selected by introducing into suspension S 100 / z1. The transformant was stroked on a plate containing SD CO. 67% non-containing amino acid YNB, 2% dextrose] to starve a single colony. Thirty clones were isolated as transformants into which pKO126 was introduced, and were named SC01 to SC30.
- SC 02, 06, 08, 1 0, 1 2, 1 3, 1 8, 1 9, 20, 22, 24, 25, 28 and 14 strains of SC 29 are plated on YPD plates and incubated at 30'C for 2 days Cultured. Inoculate a single colony with 10 clones into HI S + selective plate [Noble agar 15g, sorbitol 91g, glucose 10g, YNB (w / o) 3.35g, biotin 0.2fflg / 500ml], and incubate at 30'C for 2 days Cultured. Proliferation of all colonies was observed. It was also thought that HIS 4 gene stably maintained.
- the cells were cultured in at 30 e C 1 above the 4 strains 3 Om 1 test tube 5 m 1 Y medium (1% methanol-containing YPM medium), 46, 70, 9 of 9 hours after blowing port kinase activity CPA activity (Plasminogen activator activity) as an index], RPHA
- SCO 2, 06, 13 and SC 28 were cultured for 2 days in YPM, medium (YPM medium containing 1% methanol) and YPN! * Medium (YPM medium containing 4% methanol), respectively.
- a stamp lot of the culture was performed. Band was observed in YP M 4 medium about 50 kD a in culture cleansed of its bands are bought ⁇ especially in SC O 6.
- DNA was extracted from SCO 2.06, 10, 12, 19, 22, 29 and Pichia yeast GTS-5, respectively, and the presence of the expression cassette on the chromosome was examined by Southern method.
- the probe consisted of a 0.9 kb fragment of PHIL-D2 (manufactured by Invitrogen) corresponding to the AOX1 promoter digested with NotI-EcoRI and pMTO15 (corresponding to the structural gene for perkinase).
- XUCl-digested 1.2 kb fragment of pUC18 into which Blow-mouth kinase cDNA was incorporated) was hybridized with a DNA fragment digested with KpnI, PstI, and NcoI. Isezio Performed.
- Blow-mouth kinase secretion-expressing strain SC06 obtained in Examples 1-2 was pre-cultured in YPD medium for 30 days, subcultured twice for 2 days, and 0.01% Triton was added to YPM 2 medium containing 2% methanol.
- step (2) the area that does not contain the 52 kDa protein but has a high content of the 50 kDa protein is bulged, and is subjected to S-condensation using an ultrafiltration membrane (FILTRON STRRED CELLS: Filtron, Technology). did.
- the PA activity of 1 Oml of the concentrated solution was 43000 IU / m1, and a recovery of 90% was observed.
- PA activity of 105 IU / m1 was observed in 52 ml of the pass fraction.
- the Km value was determined and compared with the Km value of natural blow-mouth kinase (hereinafter, referred to as thrombolyse) produced by human Xu cells.
- the Km value for the synthetic substrate S-2444 color-forming synthetic reagent, manufactured by Kabi-Vitrium
- Brasmin The change over time under the activity of blow mouth kinase was not significantly different from that of thrombolyse.
- N-terminal amino acid sequence of the obtained purified blow-mouth kinase was determined.
- 2X BJ Blue Juice: lO OmM Tris HC 1 (H6.8), 43 ⁇ 4SDS, 0.2% bromophenol blue, 20 glycerol
- Add 2X BJ Blue Juice: lO OmM Tris HC 1 (H6.8), 43 ⁇ 4SDS, 0.2% bromophenol blue, 20 glycerol
- PVDF membrane At 7 OmA for 4 nights.
- the blocking buffer used was 25 mM Tris, 192 mM glycine, and 20% methanol.
- blow-mouth kinase secretion-expressing strain SC06 obtained in Examples 1 and 2 was cultured in YPD medium for 30 days, subcultured twice for 2 days, and placed in a 300-ml 1-volume flask.
- the medium 1 to 5 was inoculated into 50 ml of a methanol medium so that the absorbance (A s ⁇ .
- Fig. 5 shows the cell growth curve.
- Medium 1 and Medium 2 showed almost the same curve, and A "was changed from 2" to 2 to 23, and then decreased.
- Medium 3 increased to 41.4 on day 3 and then decreased.
- the growth on day 1 was very slow in medium 4 and medium 5, but the growth rate then increased, increasing to 36.4 on day 4 in medium 4 and 42.1 in medium 5. Since then, it has decreased.
- FIG. 6 shows the PA activity by the fibrin plate method.
- medium 1 showed an upper bound of 71 IU / ml, and then decreased.
- Medium 4 was lower than medium 2 and about twice as high.
- the activity was remarkably increased, and was 867 IU / ml on the fifth day.
- the 50 kDa band was predominant until day 3, but then decreased. However, the amount of degradation products from 29 kDa to 35 kDa as in the medium 3 was small. In the medium 5, up to the sixth day, the band of 50 kDa was mainly contained, and the amount of degradation products was small. From these results, it was found that the addition of 0.01 kappa Triton X-100 did not affect bacterial growth or suppress the molecular weight of prokinase, but the activity was increased by more than 3 times. e which is expected to have significantly suppressed adsorption to the flask mouth kinase
- Blow-mouth kinase secretion-expressing strain SC06 prepared in Examples 1-2 was cultured overnight in YPD medium (1% yeast extract, 2% bactopeptone, 2% glucose) for 30 days. Then, inoculate 30 ml of each of the culture media listed in Table 4 in a 300-ml one-volume flask so that the "" becomes 0.1 degree of S. The culture solution was cultured at 30'C for 72 hours and 144 hours. A, «, and PA activity were measured (Table 4) In the following table, Arg indicates arginine hydrochloride, and Glutamate indicates sodium glutamate.
- Table 6 shows that when 2% NH 4 H 2 PO * + 2% (NH 4 ) 2 HPO4 was added, the growth was promoted and the PA activity was higher than that of the Triton X-100 + arginine supplemented medium. It also rose 1.4 times. A stamp lot using the anti-UK antibody on this culture was performed. In YPM 2 medium was not 50 kDa band, but 5 0 kDa band was observed in 4% phosphate 3 ⁇ 4 Anmoniumu added. When Triton X-100 arginine was added, there were bands at 50 kDa and 47 kDa, and the band at 47 kDa was deeper, but when 4% ammonium phosphate was added, the band at 50 kDa was predominant. The 47 kDa band was few. From these results, it was considered that the addition of 4% ammonium phosphate suppressed the reduction of the protein from 50 kDa to 47 kDa (Fig. 7).
- Arginine ben-glutamate; 7-midine, abrotinin, casein hydrolyzate, ammonia (PA activity Roh A S ")
- the PA activity was increased 4.3 times with the addition of 0.1 IN! Glutamic acid compared to the basal medium, and was more effective than with the addition of 0.1 M arginine.
- Addition of benzyl-midine at lmM or 1 OmM reduced PA activity. 10 IU / ml abrotinin did not affect PA activity.
- 3% casamino acid of the casein hydrolyzate promotes cell growth, An increase in PA activity about 8 times that of this medium was observed.
- 4 CNH 4 C 1 suppressed cell growth and production of blow-mouth kinase. 0. 25M Na-P0 4 at pH 7. 0 or less in addition ⁇ 3 ⁇ 4 were subjected to Western plot also by PA activity was low c anti UK antibody on these culture cleanse regardless're promoted.
- ammonium salt has an effect of remarkably suppressing the reduction of the molecular weight of the 50 kDa protein.
- the reaction solution (50 ⁇ ) was placed in a siliconized conical tube, incubated at 30 for 24 hours, and the degree of decomposition of Blow ⁇ -kinase was so-called “stan-blot”. Is shown in Table 9.
- the buffer [5 OmM Tris-HCl (pH7.5), 0.5M NaC0 0.1 Triton X-100] and eluted with an eluent [0.2M glycine hydrochloride (pH 2.5), 0.5M NaCl, 0.01% Triton X-I 00]. .
- the eluate with PA activity was concentrated approximately 100-fold with molcut L (fraction molecular weight 10,000, UFP2LGC24, manufactured by Miriboa) and Ultra-free C3-LGC (fraction molecular weight 10,000, manufactured by Millipore).
- the band of 30 kDa was cut out by -PAGE, and the amino acid sequence of the 30 kDa protein obtained by extracting from the band was determined.
- the amino acid sequence of 1 matches the sequence from the isoleucine at the 159th position from the N-terminal of the blow-mouth kinase, and the amino acid sequence of 2 is 1336 from the N-terminal of the blow-mouth kinase. It matched the sequence from the lysine of the eye. This suggests that the 30 kDa protein is a small double-stranded perovin kinase.
- PA activity was measured according to the method of Levin. E. G .. et al. (Fibrin plate method, J. Cell Bio., 94, 631-636. 1982).
- Sequence type nucleic acid
- Sequence type nucleic acid
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
A process for producing a protein capable of molecular weight reduction caused by a protease of host-cell origin, which comprises culturing a host cell which can produce and secrete such a protein in at least one medium selected from the group consisting of acidic amino acids, basic amino acids, phosphate salts, ammonium salts and nonionic surfactants and separating the target protein from the supernatant of the medium. Another process for producing the above protein comprises separating the target protein by treating the supernatant with a buffer containing an ammonium salt in a column chromatograph. The invention also relates to a yeast of the genus Pichia which secretes and expresses prourokinase. This process permits the mass production in the complete form of a protein capable of molecular weight reduction caused by a protease produced by genetic engineering techniques or fermentation. It can, in addition, increase host cell growth and production of the above protein and can accelerate protein secretion from the host cell. Further, the invention process can effectively control the reduction in the molecular weight of the protein secreted in the supernatant.
Description
明 細 書 Specification
宿主細胞由来のプロテア一ゼで低分子化され得る蛋白質の製造方法 PROCESS FOR PRODUCING PROTEIN LOWER MOLECULAR BY HOST CELL PROTEASE
技 分野 Technical field
本発明は、 宿主細胞由来のプロテア一ゼで低分子化され得る不安定な蛋白質を 安定にかつ大量に製造する方法に Mする。 詳細には、 遺伝子操作により得られる 該蛋白質を産生分泌する宿主細胞を、 特定の物質を配合する培地中で培養するこ とによって宿主細胞の増殖を高めるとともに該蛋白質の產生、 分泌を促し、 かつ 低分子化を抑制することによる、 宿主細胞由来のブ口テア一ゼで低分子化され得 る蛋白質の大量製造方法に関する。 The present invention relates to a method for stably producing a large amount of an unstable protein which can be reduced in molecular weight by a protease derived from a host cell. Specifically, host cells that produce and secrete the protein obtained by genetic manipulation are cultured in a medium containing a specific substance to enhance the growth of the host cells and promote the production and secretion of the protein, and The present invention relates to a method for mass-producing a protein that can be reduced in molecular weight by a host cell-derived lipase by suppressing the reduction in molecular weight.
背景技術 Background art
棣維素溶解に係わるブラスミノーゲン活性化因子には、 血管内皮紬胞の産生す る組耩性の t一 P A、 ゥロキナーゼ(UK) などが知られている。 しかし、 ゥロ キナーゼは大量に用いると、 凝固 ·線溶諸因子の分解並びに活性化を惹起し、 出 血傾向を誘起する欠点を有している。 Known plasminogen activators involved in dialysis are tissue t-PA produced by vascular endothelial cells and perokinase (UK). However, perokinase, when used in large quantities, has the drawback of inducing the degradation and activation of coagulation and fibrinolytic factors and inducing a tendency to bleed.
これに対して、 本発明者らは人賢細胞によって産生されるヒトウ口キナーゼの 不活性型前駆物質 〔以下、 ブロウ口キナーゼという。 特開昭 6 0— 6 2 9 8 1号 公報 (E P - B - 1 3 9 4 4 7 ) 、 J. Biol. Chem.. 260, 12 377 (1985)〕 が、 血栓を構成する線維であるフイブリンに対して特異的な親和性を有し、 フィプリ ンを選択的に分解するなどの血栓溶解特性を有し、 さらに好ましいことに、 当該 ブロウ口キナーゼにはゥロキナーゼと異なり出血傾向を惹起するという欠点がな いことを見出した Cell Struc. Func.. 10, 151 (1985) 〕 。 In contrast, the present inventors have proposed an inactive precursor of human ostium kinase produced by human cells [hereinafter referred to as blow mouth kinase. Japanese Unexamined Patent Publication (Kokai) No. 60-62981 (EP-B-1 394 47), J. Biol. Chem .. 260, 12 377 (1985)] is a fiber constituting a thrombus. It has a specific affinity for fibrin, has thrombolytic properties such as the selective degradation of fibrin, and more preferably, the blow mouth kinase, unlike perokinase, causes a bleeding tendency. Cell Struc. Func .. 10, 151 (1985)] found no defect.
したがって、 このような優れた特性を有するブロウ口キナーゼは捸維素溶解酵 素として臨床上の幅広い利用が期待される。 Therefore, the blow mouth kinase having such excellent properties is expected to be widely used clinically as a fibrinolytic enzyme.
このような状況で、 近年ブロウ口キナーゼ等の有用な蛋白質を逸伝子組換え技 術を用いて大量に製造しょうとする試みがなされている。 特に分泌系を有する組 換体 (酵母) を利用する製造は、 製造された蛋白質の単雜,精製が簡便であると いう利点を有すること等からその方法について種々検討されている。 Under these circumstances, in recent years, attempts have been made to produce useful proteins such as blow mouth kinase in large quantities by using gene recombination technology. In particular, production using a recombinant (yeast) having a secretory system has been studied in various ways because of the advantage that the produced protein is simple and easy to purify.
しかし、 S ccharomyces cereuisiaeを宿主細胞とした場合は、 培地への分泌量
が低く、 大量生産が困難であることが報告されている 〔Gene, 99, 235-241,1991、 J. Biol. Chem.. 265, (2), 801-807, 1990 〕 。 However, when Sccharomyces cereuisiae is used as the host cell, And it is reported that mass production is difficult [Gene, 99, 235-241, 1991, J. Biol. Chem .. 265, (2), 801-807, 1990].
また、 本発明者らは、 ヒト血清アルブミンやインベルターゼの場合に分泌量の 増加効果が得られたピキア酵母 (Pidiifl pastoris) を宿主細胞として (Bio/ Technology, 5, 1305-1308. 1985) 、 ブロウ口キナーゼについて同様に検討した が、 ヒト血清アルブミン等の場合と比較して当該蛋白質の培地への分泌量は低く、 菌体にかなりのブロウロキナーゼが分泌されずに残存していた。 In addition, the present inventors have used Pichia pastoris, which has an effect of increasing the secretion amount in the case of human serum albumin or invertase, as a host cell (Bio / Technology, 5, 1305-1308. 1985). Although the oral kinase was examined in the same manner, the secreted amount of the protein into the medium was lower than that of human serum albumin and the like, and considerable brourokinase remained in the cells without being secreted.
さらに本発明者らは、 当該ピキア酵母を YPM培地で培養した場合、 培養上淸 にインタクトの蛋白質と思われる 5 O kDaのもの以外に 4 7 kDaや 3 0 kDa 前後の分解物が多く存在していることに気がついた。 この 4 7 kD a蛋白質は、 EGFドメイン (ェビダーマルグロ一スフアクタードメイン) を認識するモノク ローナル抗体によるゥエスタンブロットの結果からィンタクトなブロウ口キナー ゼの N末端が欠失したものであると判断され、 培養上清に存在する宿主铀胞等に 由来するプロテアーゼによって、 ブロウ口キナーゼが低分子化されるものと考え られた。 Furthermore, the present inventors have found that when the Pichia yeast is cultured in a YPM medium, there are many degradants of about 47 kDa and about 30 kDa in addition to those of 5 O kDa which are considered to be intact proteins in the culture. I noticed that This 47 kDa protein was determined to be a deletion of the intact blow-mouth kinase N-terminus from the results of ゥ -esten blotting with a monoclonal antibody recognizing the EGF domain (Evider-Malgro-factor). However, it was considered that the Blow-mouth kinase was reduced in molecular weight by proteases derived from host cells and the like present in the culture supernatant.
また、 ブロウ口キナーゼと同様に、 宿主細胞に由来するプロテアーゼにより低 分子化されてしまい、 組換え DNA技術による量産が難しい蛋白質も知られてい る (マウス EG F : Clare J. I.ら、 Gene. 105, 205 - 212. 1991; ヒト EGF : PC丁国際公開番号 WO 9 0 0 34 3 1 ; /S—ェンドルフィ ン : Bitter. G.A.ら、 Proc. Natl. Acad. Sci. USA..81, 5330. 1984等) 。 In addition, like Blow Mouth Kinase, there are also known proteins whose molecular weight is reduced by proteases derived from host cells and which is difficult to mass-produce by recombinant DNA technology (mouse EGF: Clare JI et al., Gene. 105, 205-212. 1991; Human EGF: PC D International Publication No. WO9003341; / S-endolphin: Bitter. GA et al., Proc. Natl. Acad. Sci. USA .. 81, 5330. 1984, etc. ).
従って、 このような有用な蛋白質の、 臨床分野を始めとする各分野での実用化 を図るために、 上記問題を解決し、 组換え DNA技術による有用蛋白質の製造方 法の確立が望まれている。 Therefore, in order to commercialize such a useful protein in various fields including the clinical field, it is desired to solve the above problems and establish a method for producing a useful protein by recombinant DNA technology. I have.
発明の開示 Disclosure of the invention
本発明はかかる技術的背景の下に、 宿主細胞由来のプロテア一ゼで低分子化さ れ得る蛋白質の醱酵学的もしくは遺伝子工学的手法による製造に関し、 該蛋白質 を、 低分子化されることなく大量に製造する方法を提供することを課題とする。 詳細には、 宿主細胞に、 宿主細胞由来のプロテアーゼにより低分子化され得る蛋
白質を安定にかつ大量に産生 ·分泌させ、 さらには分泌後の低分子化をも抑制す ることにより、 該蛋白質を大 Sに製造する方法を提供することを課題とする。 本発明者らは、 上記目的を達成すべく鋭意研究を重ねた結果、 組換え宿主細胞 を酸性アミノ酸、 塩基性アミノ酸、 リン酸塩、 アンモニゥム塩および非イオン性 界面活性剤から選択される少なくとも 1種を含有する培地中で培養することによ り、 宿主細胞由来のプロテアーゼにより低分子化され得る蛋白質が大量に産生 · 分泌されること及び培地中での該ブロテアーゼによる低分子化が抑制されること を見出した。 さらに、 培養上淸をアンモニゥム塩の存在下でカラムクロマトグラ フィ一で処理することにより、 目的の蛋白質の低分子化が効果的に抑制され、 大 量の目的蛋白質が培養上清から単雜できることを見出して本発明を完成した。 すなわち、 本発明は宿主細胞由来のプロテア一ゼで低分子化され得る蛋白質を 分泌產生する宿主紬胞、 就中ピキア酵母を酸性アミノ酸、 塩基性アミノ酸、 リン 酸塩、 アンモニゥム塩および非ィォン性界面活性剤からなる群から選択される少 なくとも 1種を含有する培地中で培養し、 得られる培養上清から該蛋白質を採取 することを含む宿主細胞由来のプロテア一ゼで低分子化され得る蛋白質の製造方 法乙あ Under such technical background, the present invention relates to the production of a protein that can be reduced in molecular weight by a protease derived from a host cell by an enzymatic or genetic engineering technique, wherein the protein is reduced in molecular weight. It is an object of the present invention to provide a method for mass production without mass production. Specifically, a host cell-derived protein that can be degraded by a host cell-derived protease is added to the host cell. It is an object of the present invention to provide a method for producing a large S protein by stably producing and secreting a large amount of white matter and suppressing the low molecular weight after secretion. The present inventors have conducted intensive studies to achieve the above object, and as a result, have found that the recombinant host cell is at least one selected from acidic amino acids, basic amino acids, phosphates, ammonium salts and nonionic surfactants. By culturing in a seed-containing medium, a large amount of protein that can be degraded by a host cell-derived protease is produced and secreted, and the degrading by the protease in the medium is suppressed. I found that. Furthermore, by treating the culture supernatant with column chromatography in the presence of ammonium salt, the lowering of the molecular weight of the target protein is effectively suppressed, and a large amount of the target protein can be isolated from the culture supernatant. And completed the present invention. That is, the present invention relates to a host cell that secretes and produces a protein that can be reduced in molecular weight by a protease derived from a host cell, and more particularly, to a method for transforming Pichia yeast into an acidic amino acid, a basic amino acid, a phosphate, an ammonium salt, and a nonionic interface. Culturing in a medium containing at least one selected from the group consisting of activators, and collecting the protein from the resulting culture supernatant. How to make protein
さらに本発明は、 当該製造方法における培養上清から宿主細胞由来のプロテア 一ゼで低分子化され得る蛋白質を採取する方法が、 アンモニゥム塩を含有する緩 衝液を用いて培養上淸をカラムクロマトグラフィ一で処理する、 好ましくは疎水 性カラムクロマトグラフィーおよび陽イオン交換カラムクロマトグラフィーで処 理することを含む宿主細胞由来のプロテア一ゼで低分子化され得る蛋白質の製造 方法である。 Further, the present invention provides a method for collecting a protein which can be degraded by a protease derived from a host cell from a culture supernatant in the production method, the method comprising the steps of: using a buffer solution containing ammonium salt for column chromatography on a culture supernatant; A method for producing a protein that can be reduced in molecular weight with a host cell-derived protease, which comprises treating with a hydrophobic column chromatography and a cation exchange column chromatography, preferably.
さらにまた本発明は、 ブロウ口キナーゼを産生分泌する形質転換体 (ビキア酵 母) を提供する。 Furthermore, the present invention provides a transformant (Bikia yeast) that produces and secretes blow mouth kinase.
図面の簡単な説明 BRIEF DESCRIPTION OF THE FIGURES
図 1は、 プラスミ ド p K O 1 1 0、 ρ Κ Ο 1 1 3および ρ Κ Ο 1 1 4の構築方 法を示す図である。 FIG. 1 is a diagram showing a method of constructing the plasmids p K O 110, ρ Ο 1 113, and ρ Κ Ο 114.
図 2は、 プラスミ ド p K O 1 1 6および p K O 1 1 7の構築方法を示す図であ
る 0 FIG. 2 shows a method for constructing plasmids pKO116 and pKO117. 0
図 3は、 ブラスミ ド pKO 1 2 1およびブロウ口キナーゼ分泌発現ベクター ρ ΚΟ 126の構築方法を示す図である。 FIG. 3 is a diagram showing a method for constructing brassmid pKO122 and a blow-mouth kinase secretion expression vector ρΚΟ126.
図 4は、 ブロウ口キナーゼ分泌発現ベクター pKO 1 26の制限酵素地図を示 す図である。 FIG. 4 is a diagram showing a restriction enzyme map of the blow mouth kinase secretion expression vector pKO126.
図 5は、 実験例 1における 5種類のメタノール培地で培養したピキア酵母 S C 0 6株の増殖を経時的に示した図である。 〇:培地1、 厶:培地 2、 □ :培地 3、 X :培地 4、 ·:培地 5 FIG. 5 is a graph showing the growth of Pichia yeast SC06 strain cultured in five types of methanol media in Experimental Example 1 over time. 〇: Medium 1, medium: Medium 2, □: Medium 3, X: Medium 4, ·: Medium 5
図 6は、 実験例 1における 5種類のメタノール培地でビキア酵母 SC 06株を 培養した培養上清中の Ρ Α活性を経時的に示した図である。 〇:培地1、 厶:培 地 2、 □ :培地 3、 X :培地 4、 ·:培地 5 FIG. 6 is a diagram showing the time course of the Α activity in the culture supernatant obtained by culturing the Bikia yeast SC06 strain in five types of methanol media in Experimental Example 1. 〇: Medium 1, Medium: Medium 2, □: Medium 3, X: Medium 4, ·: Medium 5
図 7は、 実験例 4で行ったウェスタンプロット (電気泳動) の結果を示す。 レーン 1 : ΥΡΜι培地使用 FIG. 7 shows the results of a Western plot (electrophoresis) performed in Experimental Example 4. Lane 1: Using ΥΡΜι medium
レーン 2 : YP 2 +2¾NH4 H2 P04 + 2¾(NH*)2 HP04 Lane 2: YP 2 + 2¾NH 4 H 2 P0 4 + 2¾ (NH *) 2 HP0 4
レーン 3および 4 : ΥΡΜί +0.01¾ トライ トン X-100 +0.1M アルギニン レーン 5および 6 : ΥΡΜ2 十 0.01¾ トライ トン X-100 +0.1M アルギニン Lanes 3 and 4: ΥΡΜί + 0.01¾ Tri-ton X-100 + 0.1M arginine lanes 5 and 6: ΥΡΜ 2 ten 0.01¾ Tri-ton X-100 + 0.1M arginine
+2¾ΝΗ4 Η2 Ρ04 + 2¾(NH4)2 HP04 + 2¾ΝΗ 4 Η 2 Ρ04 + 2¾ (NH 4 ) 2 HP0 4
発明の詳細な説明 Detailed description of the invention
本発明でいう宿主钿胞由来のプロテアーゼとは、 宿主細胞の染色体逸伝子にコ ードされるプロテアーゼをいう。 かかるプロテアーゼは、 酵母では現在約 30種 類以上見つかつており、 液胞 (yscA, yscB, yscY) 、 ミ トコンドリア(yscMpI)、 ペリブラズム(ysdl) 等に存在している。 細胞内では、 蛋白の分解、 窒素代謝、 前駆体のプロセッシング等に関与していることが知られている(Hirsch, H. H.ら, Molecular and Cell Biology of Yeasts, p.134-200. 1989)。 As used herein, the term "host cell-derived protease" refers to a protease encoded by a chromosome gene of a host cell. Such proteases are presently found in yeast in about 30 or more species, and are present in vacuoles (yscA, yscB, yscY), mitochondria (yscMpI), periplasm (ysdl) and the like. In cells, it is known to be involved in protein degradation, nitrogen metabolism, precursor processing, and the like (Hirsch, H. H. et al., Molecular and Cell Biology of Yeasts, p. 134-200. 1989).
本発明の製造方法が対象とする蛋白質は、 上記の宿主細胞由来のプロテアーゼ の作用により低分子化され得る蛋白質であれば特に限定されない。 具体的にはプ ロウ口キナーゼ、 ヒト組維ブラスミノーゲン活性化因子、 血液凝固第 IX因子、 血 液凝固第 X因子、 プロテイン c、 インターフェロン、 ェピダーマルグロ一スファ
クタ一 (以下、 EGFという) および^ーェンドルフィン等が例示される。 特に 好ましくは、 ブロウ口キナーゼである。 The protein targeted by the production method of the present invention is not particularly limited as long as it can be reduced in molecular weight by the action of the above-described host cell-derived protease. Specifically, plow-mouth kinase, human tissue plasminogen activator, blood coagulation factor IX, blood coagulation factor X, protein c, interferon, epidermal grosspha Kuta-1 (hereinafter referred to as EGF) and ^ -dolphin are exemplified. Particularly preferred is blow mouth kinase.
また本発明が対象とする蛋白質は、 天然由来の蛋白質に限定されず、 天然の蛋 白質が遺伝的に変異してなる変異体および人工的に修飾してなる誘導体であつて もよい。 例えばブロウ口キナーゼの場合、 天然型ブロウ口キナーゼのェビダーマ ルグロ一スフアクタードメインの全領域もしくはその一部を欠失、 または該全領 域もしくはその一部を他のアミノ酸残基で S換してなる蛋白質分子、 ブロウロキ ナーゼのフィンガードメインの全領域もしくはその一部を欠失、 または該全領域 もしくはその一部を他のァミノ酸残基で置換してなる蛋白質等が挙げられる 〔特 開平 3 - 87 1 8 0号 (EP - A - 3983 62) 、 特開平 3 - 87 1 8 1号 (EP-A- 3 98 36 1、 米国特許第 509884 0号) 、 特開平 5 - 9 5 7 8 6号公報 (EP— A— 54 1 9 52、 米国特許第 538 95 3 8号) 〕 。 より 具体的には、 天然型ブロウ口キナーゼの N末端から 302位のァスパラギン残基 をグルタミン酸残基に置換したブロウ口キナーゼ誘導体、 および天然型ブロウ口 キナーゼの C末端側に血栓親和性を有するァネキシン V蛋白を結合させた融合蛋 白が挙げられる (PCT国際公開番号 WO 92/ 1 9279 ) 。 これらの誘導体 は、 ァスパラギン結合型糖鎖の付加しない無糖鎖型のブロウ口キナーゼであり、 血栓親和性が高いため血栓溶解剤としての応用が期待されるものである。 Further, the protein targeted by the present invention is not limited to a naturally-derived protein, and may be a mutant obtained by genetically mutating a natural protein or a derivative obtained by artificially modifying the natural protein. For example, in the case of blow-mouth kinase, the entire region or part of the evidermal macroglobulin factor domain of the natural blow-mouth kinase is deleted, or the entire region or part thereof is S-replaced with another amino acid residue. Or a protein obtained by deleting the entire region or a part of the finger domain of bloomlokinase, or substituting the entire region or a part thereof with another amino acid residue. 87180 (EP-A-398362), JP-A-3-87181 (EP-A-398361, U.S. Pat.No. 5,098,840), JP-A-5-957786 Gazette (EP—A—54 1952, U.S. Pat. No. 538 9538)]. More specifically, a blow-mouth kinase derivative in which the asparagine residue at position 302 from the N-terminus of the natural blow-mouth kinase is substituted with a glutamic acid residue, and an annexin having thrombus affinity at the C-terminal side of the natural blow-mouth kinase And a fusion protein to which V protein is bound (PCT International Publication No. WO 92/19279). These derivatives are sugar-free blow-mouth kinases to which no asparagine-linked sugar chain is added, and are expected to be applied as thrombolytic agents due to their high thrombus affinity.
本発明で用いられる宿主細胞は、 上述のプロテアーゼにより低分子化され得る 蛋白質を分泌産生しうるものであれば特に限定されず、 天然に由来するもの及び 遗伝子操作により得られるものの別を問わない。 また、 既に公知文献に記載され ているものの他、 今後開発されるものであっても適宜利用することができる。 具体的には、 宿主細胞由来のプロテアーゼにより低分子化され得る蛋白質をコ 一ドする遗伝子を細胞内で発現して該蛋白質を産生し、 かつ菌体外に分泌する機 能を有する菌、 大腸菌, 酵母, カビおよび枯草菌等が挙げられる。 The host cell used in the present invention is not particularly limited as long as it can secrete and produce a protein that can be reduced in molecular weight by the above-mentioned protease, and it does not matter whether the host cell is naturally derived or obtained by gene manipulation. Absent. In addition to those already described in publicly known documents, those that will be developed in the future can be used as appropriate. Specifically, a bacterium having a function of expressing a gene encoding a protein that can be degraded by a host cell-derived protease in a cell, producing the protein, and secreting the protein outside the cell. , Escherichia coli, yeast, mold and Bacillus subtilis.
具体的には酵母菌、 中でもピキア属、 サッカロマイセス属であり、 より具体的 にはピキア ·パストリス (Pichiな /) a5toris) GTS 1 1 5 (his 4) (NRRL 寄託番号 Y— 1 5 85 1 ) 等が例示される。
¾伝子組換え操作により、 上記のプロテアーゼにより低分子化され得る蛋白質 を分泌産生しうる宿主細胞を調製する方法は、 公知並びにそれに準じた手法を採 用することにより実施することができる。 例えば、 ブロウ口キナーゼを産生分泌 する宿主の調製方法としては特開昭 60— 1 805 9 1号 (EP— B— 1 542 72) (サッカロマイセス厲) に記載の方法、 ヒト組織ブラスミノーゲン活性化 因子を産生分泌する宿主の詷製方法としては、 Transfusion Medicine, p303-313. (1986)に記載の方法等が例示される。 Specifically, it is a yeast, especially a genus Pichia or Saccharomyces. More specifically, Pichia pastoris (Pichi na /) a5toris) GTS 1 15 (his 4) (NRRL accession number Y—1 585 1) Etc. are exemplified. 方法 A method for preparing a host cell capable of secreting and producing a protein that can be reduced in molecular weight by the above protease by a gene recombination operation can be carried out by employing a known method or a method analogous thereto. For example, as a method for preparing a host capable of producing and secreting blow mouth kinase, a method described in JP-A-60-180591 (EP-B-154272) (Saccharomyces 厲), a human tissue plasminogen activator Examples of the method for producing a host that produces and secrete, include the method described in Transfusion Medicine, p303-313. (1986).
また、 ピキア酵母を宿主細胞とする場合は、 培地中のメタノールによって強力 に誘導される AOX遣伝子のプロモーターに目的蛋白質の S伝子を常法に従って 接挠することにより調製することができる。 この場合、 発現ベクターは、 自律增 殖型および染色体組み込み型の両者がともに用いられるが、 好ましくは染色体組 み込み型のものである。 発現ベクターとしてより好ましくは、 AOX遺伝子の 5' と 3' の非翻訳領域を両端にもち、 A OXプロモーター、 外来遗伝子、 AOXタ 一ミネータ一の他に選択マ一力一である H I S 4遠伝子を有する直鏆型べクタ一 である。 形質転換は、 スフヱロブラスト法 (Cregg, J. M.ら、 Mol. Cell. Biol.. 5. 3376-3385, 1983)、 アルカリカチオン法 (Ito, H..ら、 J. Bacterid.. 153, (1)163-168. 1983) のいずれの方法をも使用することができる。 When Pichia yeast is used as a host cell, it can be prepared by contacting the S gene of the target protein with a promoter of the AOX gene that is strongly induced by methanol in the medium according to a conventional method. In this case, both the autonomous propagation type and the chromosome integration type are used as the expression vector, but the expression vector is preferably the chromosome integration type. More preferably, the expression vector has the 5 'and 3' untranslated regions of the AOX gene at both ends, and is HIS4 which is one of the best candidates in addition to the AOX promoter, foreign gene and AOX terminator. It is a straight-type vector with a distant element. Transformation was performed by the spheroblast method (Cregg, JM et al., Mol. Cell. Biol .. 5.3376-3385, 1983), the alkali cation method (Ito, H .. et al., J. Bacterid .. 153, (1) 163). -168. 1983) can be used.
また、 宿主紬胞として好ましくはヒスチジン要求性 (h i s -) を有する株が 用いられる。 かかる株を使用することにより、 発現ベクターの導入の有無を容易 に知ることができる。 すなわち、 H 1 S 4遠伝子を含有するベクターが等入され た宿主細胞は、 そのヒスチジン栄養要求性が消失しこれをクローニングの指摞と することができるのである。 In addition, a strain having histidine auxotrophy (his-) is preferably used as a host cell. By using such a strain, whether or not the expression vector has been introduced can be easily known. That is, the host cell into which the vector containing the H1S4 gene has been equally introduced loses its histidine auxotrophy and can be used as a cloning instruction.
なお、 これまでピキア酵母の分泌発現系としては、 I nv e r t a s e Until now, the secretory expression system of Pichia yeast is Inv e r t a se
(Tschopp. J. F.. ら、 Bio/Technology, 5, 1305-1308, 1987) 、 マウス EG F (Clare. J. J.ら、 Gene. 105, 205-212, 1991) 、 ゥシライソザィム(Digan, . E, ら、 Bio/Technology, 7. 160-164. 1989) の高産生の報告があるが、 プロ ゥロキナーゼについての報告はない。 (Tschopp. JF., Et al., Bio / Technology, 5, 1305-1308, 1987), mouse EGF (Clare. JJ, et al., Gene. 105, 205-212, 1991), pencilisozyme (Digan,. E, et al., Bio / Technology, 7. 160-164. 1989), but no report on properokinase.
本発明の製造方法は、 宿主細胞由来のプロテアーゼにより低分子化され得る蛋
白質を分泌産生しうる宿主細胞を酸性アミノ酸、 塩基性アミノ酸、 リン酸塩、 ァ ンモニゥム塩及び非ィォン性界面活性剤からなる群から選択される少なくとも一 種を含有する培地で培養することを特徴とする。 これにより宿主細胞由来のブ口 テアーゼにより低分子化され得る蛋白質を完全体の状態で培養上清から大量に取 得することが可能となる。 すなわち、 当該培養方法は、 目的蛋白質の宿主細胞内 での発現、 産生効率の向上、 菌体外への分泌の促進またはプロテアーゼによる低 分子化の抑制に寄与するものと考えられる。 The production method of the present invention relates to a protein that can be reduced in molecular weight by a host cell-derived protease. Host cells capable of secreting and producing white matter are cultured in a medium containing at least one selected from the group consisting of acidic amino acids, basic amino acids, phosphates, ammonium salts, and nonionic surfactants. And This makes it possible to obtain a large amount of a protein which can be reduced in molecular weight by a host cell-derived porcine protease from the culture supernatant in an intact state. That is, the culture method is considered to contribute to expression of the target protein in host cells, improvement of production efficiency, promotion of extracellular secretion, or suppression of low molecular weight by protease.
本発明で用いられる酸性ァミノ酸としてはァスパラギン酸およびグルタミン酸 等が、 また塩基性アミノ酸としてはアルギニンおよびリジン等が例示される。 好 ましくは、 アルギニンまたはグルタミン酸である。 酸性アミノ酸および塩基性ァ ミノ酸は塩の形態で用いてもよい。 例えば、 ァスパラギン酸ナトリウム、 ァスパ ラギン酸カリウム、 グルタミン酸ナトリウム、 グルタミン酸カリウム、 アルギニ ン塩酸塩、 リジン塩酸塩が挙げられる。 Examples of the acidic amino acid used in the present invention include aspartic acid and glutamic acid, and examples of the basic amino acid include arginine and lysine. Preferably, it is arginine or glutamic acid. Acidic amino acids and basic amino acids may be used in the form of a salt. Examples include sodium aspartate, potassium aspartate, sodium glutamate, potassium glutamate, alginine hydrochloride, and lysine hydrochloride.
また、 上記に例示するァミノ酸を 1種もしくは数種組み合わせて用いることも できる。 培地中のアミノ酸含有 fiは、 通常 0. 02〜0. 5M程度、 好ましくは 0. 05〜0. 3M程度、 より好ましくは 0. 1M程度である。 In addition, one or a combination of several of the above-described amino acids can be used. The amino acid content fi in the medium is usually about 0.02 to 0.5M, preferably about 0.05 to 0.3M, and more preferably about 0.1M.
当該アミノ酸を含有する培地で本発明の宿主細胞を培養することにより、 菌体 の増殖が亢進し、 また產生された蛋白質の低分子化が抑制される効果が得られる。 本発明で用いられるリン酸塩としては、 リン酸アンモニゥム I NHJ HPO* または NH4 H2 PO« 〕 およびリン酸ナトリウム 〔Na2 HPO4 または By culturing the host cell of the present invention in a medium containing the amino acid, the effect of promoting the growth of bacterial cells and suppressing the reduction of the molecular weight of the produced protein can be obtained. Examples of the phosphate used in the present invention include ammonium phosphate I NHJ HPO * or NH 4 H 2 PO «] and sodium phosphate [Na 2 HPO4 or
NaH2 PO* 〕 等が例示される。 NaH 2 PO *] and the like.
培地中のリン酸塩の含有量は、 2〜5w/v%程度、 好ましくは 4w/v%程 度である。 The content of phosphate in the medium is about 2 to 5 w / v%, preferably about 4 w / v%.
また、 本発明で用いられるアンモニゥム塩としては、 リン酸アンモニゥ厶 〔 (NH )2 HPO* または NH« H2 PO4 〕 、 炭酸アンモニゥム 〔(NH4)2C03 または NH4 HCO3 〕 、 塩化アンモニゥム 〔NH4 C l〕 等が例示される。 培 地中のアンモニゥム塩の含有量は、 2〜5wZv¾程度、 好ましくは 4wZv% 程度でめる。
リ ン酸塩またはアンモニゥム塩として、 好ましくはリ ン酸アンモニゥムの態様 であり、 より好ましくは (NH4 ) 2 HPO* と NH4 H2 P O4 との組合せの 態様である。 培地中の (NH* ) 2 HPO* および NH4 H2 PO* の含有量と しては総量で 2〜5w/v%、 好ましくは 4wZv ¾程度が挙げられる。 As the Anmoniumu salt used in the present invention, phosphoric acid Anmoniu厶[(NH) 2 HPO * or NH «H 2 PO4], Anmoniumu carbonate [(NH 4) 2 C0 3 or NH 4 HCO3], Anmoniumu chloride [ NH 4 Cl] and the like. The content of ammonium salt in the medium is about 2 to 5 wZv%, preferably about 4 wZv%. The phosphate or ammonium salt is preferably in the form of ammonium phosphate, more preferably in the form of a combination of (NH 4 ) 2 HPO * and NH 4 H 2 PO 4 . In the medium (NH *) 2~5w / v% is a 2 HPO * and NH 4 H 2 PO * content in total, and preferably about 4wZv ¾.
リ ン黢塩またはアンモニゥム塩、 就中 (NH4 ) 2 HPO4 および ΝΗ*Η2Ρ04を 含有する培地で本発明の宿主細胞を培蹇することにより、 宿主細胞から產生分泌 されるプロテア一ゼで低分子化され得る蛋白質の低分子化が有効に抑制されると いう効果が得られる。 Li down黢塩or Anmoniumu salts, especially (NH 4) 2 HPO4 and ΝΗ * Η 2 Ρ0 by培蹇the host cell of the present invention 4 in a medium containing, Protea is產生secreted from the host cell Ichize Thus, the effect of effectively suppressing the reduction of the molecular weight of a protein that can be reduced to a lower molecular weight is obtained.
また、 本発明で用いられる非イオン性界面活性剤としては、 ポリオキシェチレ ンモノ ρ— t e r t—才クチルフヱニルエーテルおよびポリオキシエチレンソル ビ夕ン脂肪酸エステルが例示される。 好ましくはポリオキシエチレン (9〜1 0) モノ P— t e r t -ォクチルフエ二ルエーテル (商品名トライ トン X— 1 0 0、 シグマ社)、 ボリォキシエチレン ( 9) モノ ρ— t e r t—才クチルフヱニルェ 一テル (商品名ノニデッ ト P— 4 0、 シェル社) 、 ポリオキシエチレン (20) ソルビタンモノラウレート (商品名トウィーン 20、 シグマ社) 、 ポリオキシェ チレン (20) ソルビ夕ンモノォレエート) (商品名トウィーン 80、 シグマ社) 等が用いられ、 特に好ましくはトライトン X— 1 00である。 培地中の非イオン 性界面活性剤の含有量は、 0. 005〜0. 03wZv%程度、 好ましくは 0.01 Examples of the nonionic surfactant used in the present invention include polyoxyethylene mono ρ-tert-butyl tert-butyl ether and polyoxyethylene sorbin fatty acid ester. Preferably, polyoxyethylene (9 to 10) mono-P-tert-octylphenyl ether (trade name: Triton X-100, Sigma), boroxyethylene (9) mono-p-tert-octylphenyl ether (Trade name Nonidet P-40, Shell), polyoxyethylene (20) sorbitan monolaurate (trade name Tween 20, Sigma), polyoxyethylene (20) sorbitan monooleate (trade name Tween 80, Sigma) And the like, with Triton X-100 being particularly preferred. The content of the nonionic surfactant in the medium is about 0.005 to 0.03 wZv%, preferably 0.01%.
程度である。 It is about.
本発明で用いられる培地は、 上記酸性ァミノ酸、 塩基性ァミノ酸、 '' ン酸塩、 アンモニゥム塩および非イオン性界面活性剤から選択される少なくとも 1種を含 有していればよい。 好ましくは (a) 酸性アミノ酸および塩基性アミノ酸から選択 される少なく とも 1つ、 ) リン酸塩およびアンモニア塩から選択される少なく とも 1つ、 および ) 非イオン性界面活性剤を含有している態様である。 なかで もアルギニン、 リン酸アンモニゥム 〔 (NHJaHPO*および NH4H2PO« 〕 およびトライ トン X- 1 00を含有することが好ましい。 The medium used in the present invention may contain at least one selected from the group consisting of the above acidic amino acids, basic amino acids, phosphates, ammonium salts and nonionic surfactants. Preferably, an embodiment containing (a) at least one selected from acidic amino acids and basic amino acids,) at least one selected from phosphates and ammonium salts, and) a nonionic surfactant. It is. Arginine in Naka preferably contains Anmoniumu phosphate [(NHJaHPO * and NH4H 2 PO «] and 3-ton X- 1 00.
本発明で用いられる培地は、 上記の条件を演たし、 かつ宿主細胞が生育、 増殖 しうるものである限り、 他の配合成分に関しては特に制限されない。 他の配合成
分としては、 通常のこの分野で用いられる既知の培地に含まれる成分が例示され る。 例えば、 一般に炭素源として各種の糖類 (グルコース、 グリセロール等) 、 窒素源として尿素や碓酸塩等、 sss栄養素として各種ビタミン、 ヌクレオチド等 の他、 無機塩として Mg, Ca. F e, Na, K, Mn, Co, Cuの塩等が例 示される。 The other components are not particularly limited as long as the medium used in the present invention fulfills the above conditions and can grow and proliferate the host cells. Other combinations Examples of the component include components contained in a known medium commonly used in this field. For example, various sugars (glucose, glycerol, etc.) are generally used as carbon sources, urea and usate are used as nitrogen sources, various vitamins and nucleotides are used as sss nutrients, and inorganic salts such as Mg, Ca. Fe, Na, K , Mn, Co, Cu salts and the like.
具体的には、 YNB液体培地 〔0. 7¾アミノ酸非含有イーストナイトロジェ ンベース(Difco社製) 、 2%グルコース〕 、 YPD液体培地 〔1 ¾イーストェキ ストラクト(Diico社製) 、 2%バクトペプトン(Dif co社製〉 、 2%グルコース〕 等が例示される。 また、 宿主細胞が、 メタノール資化性宿主である場合には、 メ タノ一ル含有培地を使用することができる。 この場合メタノール g度は、 0.01〜 5 %程度であり、 具体的には YPM培地 〔1 %酵母抽出物、 2 パクトペプトン、 0. 0 1〜5%メタノール〕 が例示される。 Specifically, YNB liquid medium [0.7% amino acid-free yeast nitrogen base (manufactured by Difco), 2% glucose], YPD liquid medium [1 〔yeast extract (manufactured by Diico), 2% bactopeptone (Difco) Co., Ltd., 2% glucose], etc. In addition, when the host cell is a methanol-assimilating host, a methanol-containing medium can be used. Is about 0.01 to 5%, and specifically, a YPM medium [1% yeast extract, 2 pact peptone, 0.01 to 5% methanol] is exemplified.
よって、 本発明で用いられる培地は、 従来公知の培地に上記の酸性アミノ酸、 塩基性アミノ酸、 リン酸塩、 アンモニゥム塩および非イオン性界面活性剤から選 択される少なくとも 1種を添加配合することにより簡便に調製することができる。 Therefore, the medium used in the present invention is prepared by adding at least one selected from the above-mentioned acidic amino acids, basic amino acids, phosphates, ammonium salts and nonionic surfactants to a conventionally known medium. Can be easily prepared.
また、 培地の pHは中性、 弱塩基性または弱酸性のいずれであってもよい。 好 ましくは pH 6〜8である。 The pH of the medium may be neutral, weakly basic or weakly acidic. It is preferably pH 6-8.
培養は、 上記培地を用いて、 常法に準じて、 菌体が目的の蛋白質を最大量産生 し、 かつ効率よく分泌する条件を適宜選択して行うことができる。 The cultivation can be carried out by using the above-mentioned medium and appropriately selecting conditions under which the cells produce the maximum amount of the target protein and efficiently secrete it in a conventional manner.
培養温度としては、 通常 1 5〜43'C、 好ましくは 20〜3 O'Cが挙げられ、 培養時間は通常 1〜1 000時間程度が例示される。 また必要により通気下で培 養することもできる。 The culturing temperature is usually 15 to 43'C, preferably 20 to 3O'C, and the culturing time is usually about 1 to 1,000 hours. If necessary, it can be cultured under aeration.
なお、 本培養に先立って、 同様の条件で前培巷することもできる。 Prior to the main culture, preculture can be performed under the same conditions.
かくして培養した後、 培養上清に分泌された目的の蛋白質は、 培養物から公知 の分離、 精製手段により採取することができる。 例えば、 培養物を限外 ¾過もし くは遠心分雜にかけて培養上淸を取得し、 該培養上淸を硫安沈殿等の塩折、 ゲル 據過処理、 陰イオン交換体との処理、 陽イオン交換体との処理、 疎水性クロマト グラフィ一での処理等の各処理に供することにより、 目的蛋白質を精製すること
ができる。 After culturing in this manner, the target protein secreted into the culture supernatant can be collected from the culture by known separation and purification means. For example, the culture is subjected to ultrafiltration or centrifugation to obtain a culture supernatant, and the culture supernatant is subjected to salt precipitation such as ammonium sulfate precipitation, gel-based treatment, treatment with an anion exchanger, cation Purification of the target protein by subjecting it to various treatments such as treatment with an exchanger and treatment with hydrophobic chromatography Can be.
より具体的には、 本発明が対象とする目的蛋白質は宿主細胞由来のプロテア一 ゼにより低分子化されやすいため、 以下の方法により培養上淸から精製すること が好ましい。 More specifically, since the target protein of the present invention is easily degraded by a protease derived from a host cell, it is preferable to purify the target protein from the culture by the following method.
すなわち、 遠心分雜法または限外 ¾過法等の常法により、 分雜取得した培養上 淸を宿主細胞由来のプロテアーゼが混在する精製の初期段階で、 アンモニゥム塩 を含有する緩街液を用い、 低い蛋白 S度の条件下でカラムクロマトグラフィーで 処理をする方法である。 In other words, in the initial stage of purification in which a host cell-derived protease is mixed, a culture solution containing ammonium salt is used in the initial stage of purification by a conventional method such as a centrifugal separation method or an ultrafiltration method. This is a method of treating by column chromatography under the condition of low protein S.
ここで用いられる緩衝液としては、 アンモニゥム塩を含有する锾衝液であれば 特に限定されない。 好ましくは、 中性域 (p H 6〜8、 好ましくは p H 7程度) に緩衝能を有する緩衝液であり、 含有するアンモニゥム塩の濃度は 0. 05〜 5 Mが好ましい。 具体的には 0 . 0 5〜1 . 5 M リン酸アンモニゥム緩衝液 The buffer used here is not particularly limited as long as it is a buffer containing an ammonium salt. Preferably, it is a buffer having a buffering capacity in a neutral region (pH 6 to 8, preferably about pH 7), and the concentration of the contained ammonium salt is preferably 0.05 to 5 M. Specifically, 0.05 to 1.5 M ammonium phosphate buffer
( (NH<)2 H P O * および NH< H2 P O 4 を含有する。 p H 6〜8 ) が例示 される。 アンモニゥ厶塩を含有する緩衝液を用いることにより、 本発明が対象と する蛋白質のプロテアーゼによる低分子化を有効に抑制し、 インタクトな蛋白質 を高い収率で精製取得することができる。 (Containing (NH <) 2 HPO * and NH <H 2 PO 4, pH 6-8). By using a buffer containing an ammonium salt, the present invention can effectively suppress the reduction of the molecular weight of the target protein by a protease, and can purify and obtain an intact protein in a high yield.
カラムクロマトグラフィーとしては、 陰イオン交換カラムクロマトグラフィー、 陽イオン交換カラムクロマトグラフィー、 ゲル璩過カラムクロマトグラフィー、 疎水性カラムクロマトグラフィー、 キレート樹脂カラムクロマトグラフィー等の 通常蛋白質の精製、 特に醱酵または ¾伝子工学的手法により製造される蛋白質の 精製に用いられるカラムクロマトグラフィーが例示される。 なかでも本発明の好 ましい態様としては、 疎水性力ラムクロマトグラフィ一および陽ィォン交換力ラ 厶クロマトグラフィ一の組合せが挙げられる。 Column chromatography includes ordinary protein purification such as anion exchange column chromatography, cation exchange column chromatography, gel permeation column chromatography, hydrophobic column chromatography, chelate resin column chromatography, etc. Column chromatography used for purification of proteins produced by gene engineering techniques is exemplified. Among them, a preferred embodiment of the present invention includes a combination of hydrophobic force column chromatography and positive ion exchange column chromatography.
培養上清から目的蛋白質を単雜する方法として、 好ましくはアンモニゥ厶塩を 含有する緩衝液、 より好ましくはリン酸アンモニゥム緩衝液 (p H 6〜8 ) を用 いて輮水性カラムクロマトグラフィーおよび陽イオン交換カラムクロマトグラフ ィーを行う方法が挙げられ、 かかる方法により、 分解物の少ないインタク トで比 活性の高い目的蛋白質を高レ、収率で単雜することができる。
本発明で用いられる疎水性クロマトグラフィーでの処理は、 常法に従って行う ことができる。 疎水性クロマトグラフィー用担体としては、 炭素数 4〜1 8のァ ルキル基 (プチル基型、 ォクチル基型、 ォクチルデシル基型等) またはフエニル 基を有する不溶性担体が例示される。 好適にはフユニル基型が挙げられ、 具体的 にはフエ二ルーセルロース (商品名: フエニルセル口ファイン、 生化学工業社製), フエ二ルーァガロース (商品名: フエ二ルーセファロース、 フアルマシア製) 等 が例示される。 吸着、 溶出条件は、 精製する目的の蛋白質に応じて好ましい条件 を逋宜選択することができる。 As a method for isolating the target protein from the culture supernatant, aqueous column chromatography and cations are preferably carried out using a buffer solution containing ammonium salt, more preferably using an ammonium phosphate buffer solution (pH 6 to 8). There is a method of performing exchange column chromatography. By such a method, the target protein having high specific activity can be isolated at a high yield with a small amount of intact with a small amount of degraded product. The treatment by the hydrophobic chromatography used in the present invention can be performed according to a conventional method. Examples of the hydrophobic chromatography carrier include an insoluble carrier having an alkyl group having 4 to 18 carbon atoms (such as a butyl group, an octyl group, and an octyldecyl group) or a phenyl group. Preferable examples include a fuunil base type, and specific examples include phenyl cellulose (trade name: phenyl cell mouth fine, manufactured by Seikagaku Corporation) and phenyl agarose (trade name: phenyl sepharose, manufactured by Pharmacia). Is exemplified. Adsorption and elution conditions can be appropriately selected according to the target protein to be purified.
ブロウ口キナーゼの場合、 接触条件としては pH6〜8程度、 好ましくは pH 7程度、 塩濃度 0. 5〜1. 5M程度、 好ましくは 0. 5〜0. 8M程度が挙げ られる。 溶出条件としては pH6〜8程度、 好ましくは pH7程度、 塩濃度 0.05 〜0. 7M程度、 好ましくは 0. 1〜0. 5M程度、 より好ましくは 0. 2M程 度である。 In the case of blow-mouth kinase, the contact conditions include pH 6 to about 8, preferably pH 7 and a salt concentration of about 0.5 to 1.5M, preferably about 0.5 to 0.8M. The elution conditions are about pH 6 to 8, preferably about pH 7, a salt concentration of about 0.05 to 0.7 M, preferably about 0.1 to 0.5 M, and more preferably about 0.2 M.
陽イオン交換クロマトグラフィ一での処理もまた、 常法に従って行うことがで きる。 陽イオン交換体としては、 腸イオン交換基を有する不溶性担体であればい ずれも使用することができる。 ¾イオン交換基としてはカルボキシメチル (CM) 基型、 スルフォブロピル (SP) 基型等が例示される。 好ましくは SP基型であ り、 具体的には、 SP-ァガロース (商品名: S—セファロース、 フアルマシア 社製) 、 SP—デキストラン (商品名: SP-セフアデックス、 フアルマシア社 製) 等が例示される。 吸着、 溶出条件は、 精製する目的の蛋白質に応じて好まし い条件を適宜選択することができる。 The treatment by cation exchange chromatography can also be performed according to a conventional method. As the cation exchanger, any insoluble carrier having an intestinal ion exchange group can be used. ¾Examples of the ion exchange group include a carboxymethyl (CM) -based type and a sulfopropyl (SP) -based type. It is preferably an SP type, and specific examples include SP-agarose (trade name: S-Sepharose, manufactured by Pharmacia), SP-dextran (trade name: SP-Sephadex, manufactured by Pharmacia) and the like. You. Preferred conditions for adsorption and elution can be appropriately selected according to the target protein to be purified.
ブロウ口キナーゼの場合、 接触条件としては、 pH6〜8程度、 好ましくは pH 7程度、 塩纔度 0. 0 1〜0. 2M程度が挙げられる。 溶出条件としては、 pH 6〜8程度、 好ましくは pH7程度、 塩濃度 1〜1M程度が挙げられる。 In the case of blow mouth kinase, the contact conditions include pH 6 to about 8, preferably pH 7 and salt odor of about 0.01 to 0.2M. The elution conditions include about pH 6 to 8, preferably about pH 7, and a salt concentration of about 1 to 1M.
本発明によれば、 遗伝子工学的手法もしくは醱酵法により製造されるプロテア —ゼで低分子化されうる蛋白質を完全体の状態で大 Sに製造することができる。 すなわち、 本発明でいう培地で該蛋白質を分泌発現する宿主細胞を培養すること により、 宿主細胞の增琅の亢進、 該蛋白質の産生 Sの向上、 宿主細胞からの分泌
が促進される。 また、 本発明によれば、 培養上淸中に分泌された該蛋白質の低分 子化を有効に抑制することができる。 According to the present invention, a protein that can be reduced in molecular weight by a protease produced by a genetic engineering technique or an enzymatic method can be produced in large form in large size in a complete state. That is, by culturing a host cell that secretes and expresses the protein in the medium referred to in the present invention, it enhances the expression of the host cell, improves the production S of the protein, and secretes the protein from the host cell. Is promoted. Further, according to the present invention, it is possible to effectively suppress the low molecular weight of the protein secreted into the culture medium.
なかでも、 本発明で用いる非イオン性界面活性剤は、 宿主細胞の增殖や蛋白質 の低分子化抑制には直接寄与しないが、 蛋白質の器具等への吸着等による消失を 抑制する効果を奏する。 アミノ酸、 就中アルギニンやグルタミン酸は宿主細胞の 増殖を亢進し、 産生される蛋白質の低分子化を抑制する効果を奏する。 またリン 酸アンモニゥムは蛋白質の低分子化を効果的に抑制する。 しかもこれらのものを 組み合わせることにより、 宿主細胞の増殖および蛋白質の産生分泌は相乗的に向 上する。 Among them, the nonionic surfactant used in the present invention does not directly contribute to the growth of host cells or the suppression of protein depolymerization, but has an effect of suppressing the disappearance of proteins by adsorption to instruments and the like. Amino acids, especially arginine and glutamic acid, have the effect of increasing the growth of host cells and inhibiting the production of low-molecular-weight proteins. In addition, ammonium phosphate effectively suppresses the reduction of protein molecular weight. Furthermore, by combining these, the growth of host cells and the production and secretion of proteins are synergistically improved.
さらに本発明の単雜方法によれば、 堉製段階で低分子化されやすい蛋白質の分 解を有効に抑制し、 完全体の蛋白質を高い収率で効率よく精製単雜することがで きる。 また、 本発明により、 初めてブロウ口キナーゼを分泌産生することができ るピキア酵母 (形質転換体) を提供することができる。 Further, according to the unification method of the present invention, it is possible to effectively suppress the decomposition of proteins that are liable to be reduced in molecular weight at the stage of production, and to efficiently purify and intact intact proteins in high yields. Further, the present invention can provide, for the first time, a Pichia yeast (transformant) capable of secretory production of a blow mouth kinase.
実施例 ·実験例 Examples and experimental examples
本発明をより詳細に説明するために、 以下に実施例、 実験例および参考例を挙 げるが、 本発明はこれらにより何ら限定されるものではない。 The present invention will be described in more detail with reference to Examples, Experimental Examples and Reference Examples below, which should not be construed as limiting the present invention.
ここで用いた全ての酵素は、 とくに断らない限り商業的供給源、 例えば宝酒造 株式会社等から入手したものである。 酵素反応のための緩衝液および反応条件は 特に断らない限り各酵素の製造元の推奨に従った。 All enzymes used herein were obtained from commercial sources, such as Takara Shuzo Co., unless otherwise noted. Buffers and reaction conditions for enzyme reactions were according to the manufacturer's recommendations for each enzyme unless otherwise noted.
%は特に断らない限り w/v%である。 なお、 NH4 -PO* は ( H*)2HPC お よび腿 4 H2 PO4 を含有するリン酸アンモニゥム緩衝液を意味し、 Na—P0* は Na2 HPO« および NaH2 P 0«.を含有するリン酸ナトリウム锾街液を意 味する。 % Is w / v% unless otherwise specified. NH 4 -PO * refers to ammonium phosphate buffer containing (H *) 2 HPC and thigh 4 H 2 PO4, and Na—P0 * refers to Na 2 HPO «and NaH 2 P 0«. Means the contained sodium phosphate 锾 city liquid.
実施例 1 ブロウ口キナーゼ発現べクタ一、 PK0126の構築 Example 1 Construction of Blow Mouth Kinase Expression Vector, PK0126
pUC 1 9を Hi ndlllで消化した後に、 DN Aボリメラーゼのクレノウ断 片で fill-inを行い、 pXhol リンカ一 [d(pCCTCGAGG)]を付加してライゲーシヨン した。 アンピシリン、 イソプロピル一^一 D—チオーガラクトピラノシド ( I P TG ), 5—プロモー 4一クロ口一 3—インドリル一 8— D—ガラクトシド (X
-GAL) を含む LB培地中で青色を呈するコロニーから調製したブラスミ ドを pKO 1 1 0と命名した。 当該ブラスミ ドの大きさは pUC 1 9と大差がなく欠 失がないことが予想され、 また Xh o 1認識部位を有していることが確認された c 尚、 このブラスミ ドを有する形質転換体が I PTG、 X— GALを含む LB培地 上で青色を呈した理由は挿入した D N A断片が短く、 かつ挿入によつて遺伝子の 読み枠がずれなかったためであると推測される。 After digesting pUC19 with Hindlll, fill-in was performed with Klenow fragment of DNA bolimerase, and ligation was performed by adding pXhol linker [d (pCCTCGAGG)]. Ampicillin, isopropyl-1-D-thio-galactopyranoside (IPTG), 5-promo 4-chloro-1,3-indolyl 8-D-galactoside (X -GAL) -containing plasmid was prepared from a blue-colored colony in an LB medium and named pKO110. Size of the Burasumi de is expected that no deletions without pUC 1 9 so different and Xh o 1 to have a recognition site was confirmed c Note that a transformant having this Burasumi de It is presumed that the reason for the blue color on LB medium containing IPTG and X-GAL was that the inserted DNA fragment was short and that the insertion frame did not shift due to the insertion.
厶コール · レンニン遗伝子由来のシグナル配列とブロウ口キナーゼ cDNAを inframeで接接した ¾伝子を含む Sacch ronyces cerevisiae用の発現ベクター であるブラスミ ド JUK I (平松ら、 Gene. 99. 235-241. 1991 、 特開平 3— 2 4 04 93号公報、 特開平 4 - 1 66088号公報参照) を B 1 IIで部分消化 した後に、 P s t Iで消化して、 シグナル配列の一部とブロウ口キナーゼ cDN Aの一部を含む 330 bpの断片を分離した。 なお、 後記配列表配列番号 1にブ ラスミ ド JUK 1が含有するムコール ' レンニン遺伝子由来のシグナル配列のァ ミノ酸配列及び塩基配列を示す。 OPCカラム (アブライド 'バイオシステムズ ジャパン社製) を用いて精製した 5 jiigずつのリンカ一 aと b (表 1 ) に T4ボ リヌクレオチドキナーゼと ATPを添加して 37'Cで 30分間孵置して、 5' 末 端をリン酸化した。 Plasmid JUKI (Hiramatsu et al., Gene. 99. 235-), an expression vector for Sacch ronyces cerevisiae containing a gene in which a signal sequence derived from the gene and the Blow Mouth Kinase cDNA are connected in frame. 241. 1991, JP-A-3-240493 and JP-A-4-166088) were partially digested with B1II and then digested with PstI to obtain a part of the signal sequence and A 330 bp fragment containing a portion of the oral kinase cDNA was isolated. The amino acid sequence and the base sequence of the signal sequence derived from the mucor rennin gene contained in the plasmid JUK1 are shown in SEQ ID NO: 1 in the Sequence Listing below. T4 polynucleotide kinase and ATP are added to 5 jiig linkers a and b (Table 1) purified using an OPC column (Abride 'Biosystems Japan) and incubated at 37'C for 30 minutes. To phosphorylate the 5 'end.
表 1 合成したリンカ一 aと bの塩基配列 リ ンカ一 a : 5· - TCGAGATGTTGTTCTCTAA - 3' Table 1 Base sequences of synthesized linkers a and b. Linker a: 5 ·-TCGAGATGTTGTTCTCTAA-3 '
リ ンカ一 b : 3'- CTACAACAAGAGATTCTAG- 5' Linker b: 3'-CTACAACAAGAGATTCTAG-5 '
これらリンカ一 a, bを混合して 70でで 20分間加熱した後、 室温に放置し て徐冷した。 ァニーリングしたリンカーとブラスミ ド JUK 1から調製した 330 b pの P s t I -Bg 1 II断片を混合してライゲージヨンした後、 エタノール沈
©を行い DNAを回収した。 沈殺を TE ClOmM Tr i s— HC 1 (pH8.0), 1 mM EDTA〕 に溶解後、 P s t I— B g 1 II断片を混合してライゲーショ ン後、 エタノール沈 Sを行い DNAを回収した。 該沈澱を TEに溶解後、 P s t I -Xho Iで消化して 36 O b pの断片を分雜した。 この断片を pKO l 1 0 から調製した 2. 7 kbの P s t l— Xho I断片とライゲーシヨンした後に大 腸菌に導入して形質転換を行った。 39クローンのアンピシリン 性コロニーか らブラスミ ドを分離した。 制限酵素消化による一次スクリーニングを行い 6クロ ーンのブラスミ ドを選びだして、 導入したリンカ一近傍の塩基配列をリキッ ドフ エーズ.シークェンサ一 (フアルマシア社製) で調べたところ、 5クローンの塩 基配列は期待通りの配列であった (配列表、 配列番号 2) 。 2クローンを選び出 して pKO I 1 3および pKO 1 1 4 (3. 05 kb) と命名した (図 1〉 。 ムコール . レンニンのシグナル配列とブロウ口キナーゼ c DNAを inframe で 接続した遺伝子を含む Sflccfca mycM cerevisiae用の発現べクタ一であるブラ スミ ド N 302 Qから調製した 8 9 O b pの P s t I - B a mH I断片を p U C 1 9にクローニングして pKO 1 1 1を得た。 さらに pKO 1 1 1から 890b p の P s t I— BamH I断片を調製して、 該断片を pKO 1 1 3の P s t I— B amH I部位へクローニングしてブラスミ ド pKO 1 1 6および pKO 1 1 7 (3. 95 kb) を得た (図 2) 。 なお、 ブラスミ ド N 302 Qは、 ブラスミ ド JUK Iのブロウ口キナーゼ c DN Aの N末端から 302番目のァミノ酸である ァスパラギン酸のコドン AATをグルタミンのコドン CAGに、 site-specific mutagenesis法 (Molecular Cloning, A Laboratory Manual. Second edition. Sambrook. J.ら編、 1989年、 Cold Spring Harbor Laboratory, New York)によつ て改変したものであり、 ァスパラギン結合型糖鎖付加部位が消失している。 These linkers a and b were mixed and heated at 70 for 20 minutes, and then allowed to cool to room temperature. The annealed linker and 330 bp PstI-Bg1II fragment prepared from Brasmid JUK1 were mixed and ligated, followed by ethanol precipitation. © was performed to recover DNA. The precipitate was dissolved in TEClOmM Tris-HC1 (pH8.0), 1 mM EDTA], mixed with a PstI-Bg1II fragment, ligated, and ethanol precipitated S to recover DNA. . The precipitate was dissolved in TE, and digested with PstI-XhoI to isolate a 36-Obp fragment. This fragment was ligated with a 2.7 kb Pstl-XhoI fragment prepared from pKO110 and then introduced into Escherichia coli for transformation. Brasmid was isolated from 39 clones of ampicillinous colonies. Primary screening by restriction enzyme digestion was carried out to select 6 clones of plasmid, and the nucleotide sequence in the vicinity of the introduced linker was examined with a liquid phase sequencer Quensa-1 (Pharmacia). The sequence was as expected (sequence listing, SEQ ID NO: 2). Two clones were selected and named pKO I13 and pKO114 (3.05 kb) (Fig. 1). Mucor. Contains the gene that connects the signal sequence of rennin and the cDNA of the blow mouth kinase in frame. An 89 Obp PstI-BamHI fragment prepared from plasmid N302Q, an expression vector for Sflccfca mycM cerevisiae, was cloned into pUC19 to obtain pKO111. Further, a PstI—BamHI fragment of 890 bp from pKO111 was prepared, and this fragment was cloned into the PstI—BamHI site of pKO113 to obtain plasmids pKO116 and pKO116. 11.7 (3.95 kb) was obtained (Fig. 2). Brasmid N302Q is aspartic acid, the 302th amino acid from the N-terminus of the brass-mouth kinase cDNA of Brasmid JUKI. Codon AAT of glutamine to CAG of glutamine, site-specific mutagenesis method (Molecular Cloning, A Laboratory Manual. Second edition. Sambrook. J. et al., 1989, modified by Cold Spring Harbor Laboratory, New York), in which the asparagine-linked glycosylation site has disappeared.
pKO 1 1 6を B amH Iと Κρη Iで消化して 3. 95 kbの DNA断片を 分雠した。 一方、 ブロウ口キナーゼ c DNAを含む哺乳類細胞用発現べクタ一で ある p SV— G 1 - UK 〔特開昭 63 - 1 05 675号公報 (EP - A - 2 6 5 8 74 ) 参照〕 を B amH Iと Kpn Iで消化して 320 b ρの DNA断片を取 得し、 P KO 1 1 6の DNA断片 (3. 95 kb) にライゲートしてブラスミ ド
pKO 1 1 8を得た。 ρΚΟ 1 1 8を Κρη Iで消化した後に Τ 4 DN Αボリメ ラーゼを用いて平滑末端とした後、 pXho I リンカ一 (宝酒造社製) を付加し た。 Xh o I消化によって、 1.57k bの断片を分雔して pKO 1 1 0の Xh o I サイトへクローニングしてブラスミ ド pK0121 を得た。 PK0121 を Xh o I で消化して 1. 57 kbの DNA断片を分離して、 pA0807NXの Xh o I サイトにクローニングをした。 ィンサートの方向が順方向である pKO 1 2 6を 分離した (図 3、 図 4) ο なお、 p AO 807 NXはブラスミ ド pH I L— D 2 (インビトロゲン社製) のクローニング部位である E c oR I認識部位を Xhol認 識部位に変換したブラスミ ドである (ブラスミ ド pH I L— D2を E c oR I消 化し、 クレノウ断片により fill-in し、 pXho I リンカ一を付加したのち、 Xh o I消化した断片を分雜してライゲーシヨン反応を行い p AO 8 07 NXを 調製した) 。 pKO116 was digested with BamHI and ΚρηI to separate a 3.95 kb DNA fragment. On the other hand, p SV—G 1 -UK, which is an expression vector for mammalian cells containing blow mouth kinase cDNA (see Japanese Patent Application Laid-Open No. 63-105675 (EP-A-2656784)). A 320 bp DNA fragment was obtained by digestion with BamHI and KpnI, ligated to a PKO116 DNA fragment (3.95 kb), and excised pKO 118 was obtained. ρΚΟ118 was digested with ΚρηI, blunt-ended with Τ4DNΑvolimerase, and then added with pXhoI linker (Takara Shuzo). The 1.57 kb fragment was separated by XhoI digestion and cloned into the XhoI site of pKO110 to obtain the plasmid pK0121. PK0121 was digested with XhoI to isolate a 1.57 kb DNA fragment, which was cloned into the XhoI site of pA0807NX. PKO126 was isolated with the insert inserted in the forward direction (Figures 3 and 4). Ο pAO807Nx is a cloning site for plasmid pHIL-D2 (Invitrogen) Ec This is a plasmid in which the oR I recognition site has been converted to an Xhol recognition site (Esco R I digestion of the plasmid pH IL-D2, fill-in with Klenow fragment, addition of pXho I linker, and then Xho I digested fragments were ligated and ligation reaction was performed to prepare pAO80707NX).
実施例 2 形質転換体の取得 Example 2 Obtaining a transformant
実施例 1で得られた pKO 1 26 ( 1 O ii g) をザィモリレース消化後、 塩化 カルシウム処理してコンビテントな状態にしたピキア酵母 iPichia pastoris GTS 1 1 5 : NRRL寄託番号 Y— 1 585 1 ) 懸 S液 1 00 /z 1に導入し、 H I S+ の形質転換体を選択した。 該形質転換体を SD CO. 67% 非含有ァ ミノ酸 YNB, 2%デキストロース〕 プレート上でストロークして単一コロニー を分饑した。 pKO 1 26を導入した形質転換体として 30クローンを分離して SC 0 1〜SC 30と名付けた。 PKO126 (1Oiig) obtained in Example 1 was digested with zymorylacese, and treated with calcium chloride to make it a competent Pichia yeast iPichia pastoris GTS 115: NRRL deposit number Y—15851) HI S + transformant was selected by introducing into suspension S 100 / z1. The transformant was stroked on a plate containing SD CO. 67% non-containing amino acid YNB, 2% dextrose] to starve a single colony. Thirty clones were isolated as transformants into which pKO126 was introduced, and were named SC01 to SC30.
上記で得られたブロウ口キナーゼ分泌発現株 SC 0 1〜SC 30の中からプロ ゥロキナーゼ產生量の多い株を選択するために、 各株の性状を調べた。 The properties of each strain were examined in order to select a strain having a high prokinase production amount from the blow-mouth kinase-secreting strains SC01 to SC30 obtained above.
( 1 ) H I S 4遣伝子の安定性 (1) Stability of HIS 4 gene
SC 02, 06, 08, 1 0, 1 2, 1 3, 1 8, 1 9, 20, 22, 24, 25, 28及び SC 29の 1 4株を YPDプレートに蒔き、 30'Cで 2日間培養 した。 単一コロニーを 1 0クローンづっ、 H I S+ 選択ブレート [Noble agar 15g,ソルビトール 91g, グルコース 10g, YNB(w/o) 3.35g,ピオチン 0.2fflg/500ml〕 に植菌し、 30'Cで 2日間培養した。 全てのコロニーの増殖が観察され、 いずれ
も H I S 4逸伝子を安定に保持しているものと考えられた。 SC 02, 06, 08, 1 0, 1 2, 1 3, 1 8, 1 9, 20, 22, 24, 25, 28 and 14 strains of SC 29 are plated on YPD plates and incubated at 30'C for 2 days Cultured. Inoculate a single colony with 10 clones into HI S + selective plate [Noble agar 15g, sorbitol 91g, glucose 10g, YNB (w / o) 3.35g, biotin 0.2fflg / 500ml], and incubate at 30'C for 2 days Cultured. Proliferation of all colonies was observed. It was also thought that HIS 4 gene stably maintained.
(2) 培養 (2) Culture
上記の 1 4株を 3 Om 1試験管中 5m 1の Y 培地 (メタノール 1 %含有 YPM培地) で 30eCで培養を行い、 46, 70, 9 9時間後のブロウ口キナー ゼ活性 CPA活性 (plasminogen activator 活性) を指標として測定〕 、 RPHAThe cells were cultured in at 30 e C 1 above the 4 strains 3 Om 1 test tube 5 m 1 Y medium (1% methanol-containing YPM medium), 46, 70, 9 of 9 hours after blowing port kinase activity CPA activity (Plasminogen activator activity) as an index], RPHA
(reversed passive haniagglutination)、 A"。 を測定した。 その結果、 PA活 性は、 SC 0 6, 08, 1 2が比較的高かった。 A"。 は吸光度が 20以下のも の (SC 0 6, 08, 1 0, 1 9, 22) と、 30以上のもの (S C 0 2, 1 2, 1 3, 1 8, 20, 24, 25, 28, 29 ) とに大別された。 これらの株のう ち P A活性が比較的高く增殖度の悪い SC 0 6と増殖度の良い SC 1 2を 5 0ml YPMZ300 m lフラスコでメタノール濃度を 1 , 2, 3, 4, 5 に変えた 条件で培養した。 その結果、 SC 06ではメタノール S度 2%および 3 %の培地 での 7 1時間培養で約 20 I U/mし SC 1 2ではメタノール濃度 3 %の培地 での 7 1時間培養で約 4. 6 1 UZm 1の発現が認められた。 (reversed passive haniagglutination), A ". As a result, the PA activity was relatively high in SC06, 08, and 12. A". Are those with an absorbance of 20 or less (SC 0 6, 08, 10, 9, 22) and those with an absorbance of 30 or more (SC 0 2, 12, 2, 3, 18, 19, 24, 25, 28 , 29). Among these strains, SC06 with relatively high PA activity and poor growth rate and SC12 with good growth rate were used in a 50 ml YPMZ 300 ml flask with the methanol concentration changed to 1, 2, 3, 4, 5 And cultured. As a result, in SC06, about 20 IU / m was cultured in a medium containing 2% and 3% methanol S for 71 hours, and in SC12, about 4.6 hours in a medium containing 3% methanol for 71 hours. Expression of 1 UZm1 was observed.
( 3 ) ウェス夕ンブロット (3) Wes evening blot
SC O 2, 06, 1 3および SC 28について、 YPM, 培地 (メタノール 1 %含有 YPM培地) および YPN!* 培地 (メタノール 4%含有 YPM培地) でそ れぞれ 2日間培養して、 得られた培養上淸のゥヱスタンプロットを行った。 YP M4 培地の培養上淸に約 50 kD aのバンドが認められ、 特に SC O 6でそのバ ンドが瘼かった。 SCO 2, 06, 13 and SC 28 were cultured for 2 days in YPM, medium (YPM medium containing 1% methanol) and YPN! * Medium (YPM medium containing 4% methanol), respectively. A stamp lot of the culture was performed. Band was observed in YP M 4 medium about 50 kD a in culture cleansed of its bands are bought瘼especially in SC O 6.
(4) サザンブロット (4) Southern blot
SC O 2. 06, 1 0, 1 2, 1 9, 22, 29およびピキア酵母 G T S Π5 からそれぞれ DNAを抽出し、 染色体上の発現カセットの存在状態をサザン法に より調べた。 プローブは、 AOX 1プロモーターに相当する PH I L— D 2 (ィ ンビトロゲン社製) を No t I— E c oR I消化した 0. 9 kb断片とゥロキナ ーゼの構造遺伝子に相当する pMTO 1 5 (pUC 1 8にブロウ口キナーゼの c DNAが組み込まれたベクター) を Xho l消化した 1. 2 kb断片を使用し、 Kp n I, P s t I, Nc o Iで消化した DNA断片とのハイブリダィゼーショ
ンを行った。 これらの結果から、 増殖度が悪くかつ PA活性も低い SC10, 19お よび 22株は発現カセットがシングルコピーで AOX 1サイトに置換された伏態 で存在していると予想された。 また増殖度は悪いが P A活性が高い SC 0 6株は 発現カセットがダブルコピーで AOX 1サイトに置換された伏態で存在していた e —方、 增殖度の良い SC 02および 1 2株は凳現カセットがマルチコピーで AO X 1サイトに挿入された形で組み込まれており、 SC 29株は発現カセットが A OX 1サイト以外のサイトに組み込まれていると予想された (表 2) 。 尚、 表中 Sとは、 s 1 owを意味する。 DNA was extracted from SCO 2.06, 10, 12, 19, 22, 29 and Pichia yeast GTS-5, respectively, and the presence of the expression cassette on the chromosome was examined by Southern method. The probe consisted of a 0.9 kb fragment of PHIL-D2 (manufactured by Invitrogen) corresponding to the AOX1 promoter digested with NotI-EcoRI and pMTO15 (corresponding to the structural gene for perkinase). XUCl-digested 1.2 kb fragment of pUC18 into which Blow-mouth kinase cDNA was incorporated) was hybridized with a DNA fragment digested with KpnI, PstI, and NcoI. Isezio Performed. From these results, it was expected that the SC10, 19 and 22 strains, which had poor growth and low PA activity, would be present in a single copy with the expression cassette substituted at the AOX1 site. The degree of proliferation is bad was present in facedown state the PA activity is high SC 0 6 strains expression cassette is replaced with AOX 1 site Double copy e - way, good SC 02 and 1 2 strains of增殖degree凳 The current cassette was integrated in a form inserted into the AOX1 site in multiple copies, and the SC29 strain was expected to have the expression cassette integrated into a site other than the AOX1 site (Table 2). In the table, S means s 1 ow.
表 2 Table 2
SC株の発現カセットの存在状態 クローン 増殖 PA活性 存在数 存在状態 存在部位 Existence status of SC strain expression cassette Clones Proliferation PA activity Existence status Existence site
S C 1 0 S + single 置換 A0X-1S C 1 0 S + single Replace A0X-1
SC 1 9 S + single 置換 A0X-1SC 1 9 S + single Replace A0X-1
S C 22 S +· single 置換 A0X-1S C 22 S + single replacement A0X-1
S C 0 6 S ++++ 2 置換 A0X-1S C 0 6 S ++++ 2 Replacement A0X-1
SC 02 十 ++ multi 揷入 A0X-1SC 02 10 ++ multi import A0X-1
S C 1 2 + 十+十 multi 挿入 A0X-1S C 1 2 + Ten + Ten multi Insert A0X-1
SC 29 + + multi 挿入 SC 29 + + multi insertion
実施例 3 形質転換体の培養 Example 3 Culture of transformant
実施例 1〜2で得られたブロウ口キナーゼ分泌発現株 S C 0 6を YPD培地で 3 0て、 2日間 2回植え継ぎながら前培養し、 メタノール 2%含有の YPM2 培 地に 0.01%トライトン X— 100、 0.1 Mアルギニン塩酸塩、 2%(NH4)2HPO, および 2%NH4 H2 P04 を配合してなる培地 0. 5リットルに 540 nmの
吸光度 (AS4。 ) が 0. 1となるように植菌し、 3 O'Cで 3日間培養した。 Blow-mouth kinase secretion-expressing strain SC06 obtained in Examples 1-2 was pre-cultured in YPD medium for 30 days, subcultured twice for 2 days, and 0.01% Triton was added to YPM 2 medium containing 2% methanol. X- 100, 0.1 M arginine hydrochloride, 2% (NH4) 2 HPO , and 540 nm in 2% NH 4 H 2 P0 4 medium 0.5 liters obtained by blending Absorbance (A S4.) Is inoculated so that 0.1, and cultured for 3 days in 3 O'C.
実施例 4 ブロウ口キナーゼの単雜 Example 4 Blow Mouth Kinase Simplex
(1) フエ二ルセファロース一カラムク Dマトグラフィー (1) Phenylsilpharose-single column chromatography D-matography
実施例 3で得られた培養上淸 2. 86リットルに、 2M Nt — PO pH 7. 0 ) 772mlを加えて、 最終 g度 0. 7M NH* - P C となるように 調製し、 当該溶液を平衡化用緩衝液 0. 7M NH* -PO« (pH7. 0) で 平衡化したフエ二ルセファロースカラム (5 cm i . d. x 7. 8 cm : 150 m l、 フアルマシア社製) に 1 90ml /hrの流速で添加した。 添加後、 同平 衡化用缓衝液 750 mlで洗浄し (washl)、 さらに洗浄用緩衝液 〔0. 5M NH« -PO (pH7. 0) 〕 750 mlで洗净した (washll)。 その後、 溶 出用緩衝液 [elute 〖 : 0. 2M NH« -PO (pH7. 0 ) 〕 1200m 1で 1 50m 1ずつ 8本分取し、 さらに溶出用緩衝液 Celute II: 0.05M NH4 一 P0 (pH7. 0) 〕 750 m 1、 溶出用緩衝液 Celutelll: 1%トライトン X— 1 00, 0. 05M Na— PO, (pH7. 0) 〕 1リッ トルで溶出した。 各面分の P A活性を測定すると、 活性成分はパス溶出液及び wash Iにはほとんど 溶出されず、 washllに 6%、 elute Iに 90%、 elute IIと elutelllが各々 0.4 %であり、 elute Iに大部分の活性が認められた。 To 2.8 liters of the culture obtained in Example 3, 772 ml of 2M Nt—PO pH 7.0) was added to prepare a final g degree of 0.7M NH * -PC. Equilibration buffer 0.7 M NH * -PO «(pH 7.0) Equilibrated with a Phenyl Sepharose column (5 cm i.d. x 7.8 cm: 150 ml, manufactured by Pharmacia) was added at a flow rate of / hr. After the addition, the mixture was washed with 750 ml of a buffer for equilibration (washl), and further washed with 750 ml of a washing buffer [0.5 M NH «-PO (pH 7.0)] (washll). Thereafter, for elute buffer [elute 〖: 0. 2M NH «-PO (. PH7 0) ] 1 50 m 1 each were collected 8 duty at 1200 m 1, further elution buffer Celute II: 0.05M NH 4 one P0 (pH 7.0)] 750 ml, elution buffer Celutelll: 1% Triton X—100, 0.05 M Na—PO, (pH 7.0). When the PA activity of each surface was measured, the active components were hardly eluted in the pass eluate and wash I, and 6% for washll, 90% for elute I, 0.4% for elute II and elutelll each, and elute I Most of the activity was observed.
次に、 各溶出画分について抗 UK抗体によるゥ スタンブロットを行ったとこ ろ、 パス溶出液及び wash Iにはバンドは認められず、 washllには 5 OkDaと 47 kD aとが同程度存在していた。 elute Πにはバンドが認められず、 elutelUに は 30 kD a以下の大部分の分解物が溶出された。 elute 〗では面分 1及び 2に 50 kD aのバンド以外に 47 kD aの明確なバンドが認められ、 画分 3以降で は 50 kD aのメインバンドの他は 47 kD aの含童が少なく、 40 kD a以下 の分解物が多少存在していた。 そこで、 47 kD aの含量が少なく P A活性が高 かつた靣分 3から面分 6をブールして、 次のステツブに供した。 Next, when each eluted fraction was subjected to a Western blot with an anti-UK antibody, no band was observed in the pass eluate and wash I, and 5 OkDa and 47 kDa were present in the same amount in washll. I was No band was observed in elute II, and most of the degradation products of 30 kDa or less were eluted in elutelU. In elute〗, a clear band of 47 kDa other than the band of 50 kDa was recognized in the facets 1 and 2, and after fraction 3, there was little child of 47 kDa other than the main band of 50 kDa. However, some degradation products of 40 kDa or less were present. Therefore, fraction 3 to fraction 6 which had a low content of 47 kDa and a high PA activity were subjected to the next step.
(2) Sセファロースカラムクロマトグラフィー (2) S Sepharose column chromatography
( 1 ) で得られた画分 3から画分 6のブール 600mlに 1%トライトン X— 1 00 1 2m 1と水 588 m 1とを加え、 平衡化用緩衝液 〔0. 01¾トライ
1 トン X— 1 0 0, 0. 1 M NH4 -PO4 (pH 7. 0) 〕 で平衡化した Sセ ファロースカラム 〔2. 5 cm i . d. x 6. 1 cm: 30m フアルマシ ァ社製〕 に流速 6 Om lZh rで添加した。 添加後、 平衡化用緩衝液 1 5 0m l で洗浄し (washl) 、 さらに洗浄用緩衝液 !: washll: 0. 1 Na C】 i n 0. 05M Na-P04 (pH7. 0) , 0. 0 1 %トライトン X— 1 0 0〕 1 5 Om 1で洗浄後、 溶出用緩衝液 〔0. 1〜0. 5M N a C 1 g度勾配 i n 0. 05M Na-PO* (pH7. 0) 、 0. 0 1 ¾トライ トン X— 1 0 0〕 3 0 Om lで溶出した。 その結果、 パス溶出液、 washl、 washllには、 PA活性 は殆ど認められず、 0. 2〜0. 3M NaC 1の溶出面分に PA活性が認めら れ、 A2,。 の吸光度と一致した。 各面分を銀染色でみると、 面分 4 8まではバン ドは認められず面分 50から面分 56に 52 kDaの薄いバンドが存在し、 5 0 kD aバンドは画分 50から面分 68に存在しており、 濃い 50 kDaバンドが 存在する画分 57から画分 62には、 多少の分解物が確認された。 1% Triton X—100 1 2 ml and 588 ml of water were added to 600 ml of the boule of fractions 3 to 6 obtained in (1), and the buffer for equilibration [0.01 S-Sepharose column equilibrated with 1 ton X—100, 0.1 M NH 4 -PO4 (pH 7.0)] [2.5 cm i.d. x 6.1 cm: 30 m Pharmacia Was added at a flow rate of 6 OmlZhr. After addition, wash with 150 ml of equilibration buffer and wash buffer! : Washll: 0. 1 Na C] in 0. 05M Na-P0 4 ( . PH7 0), washed with 0.0 1% Triton X- 1 0 0] 1 5 Om 1, elution buffer [0. It was eluted with 1-0.5 M NaC 1 g gradient in 0.05 M Na-PO * (pH 7.0), 0.01 @ triton X—100] 30 Oml. As a result, almost no PA activity was observed in the pass eluate, washl and washll, and PA activity was observed in the elution area of 0.2 to 0.3 M NaCl, and A 2 ,. And the absorbance of the sample. When silver was stained for each area, no band was observed up to area 48, and a thin band of 52 kDa was present in areas 50 to 56, and the 50 kDa band was observed in area 50 from area 50. Some degradation products were observed in fractions 57 to 62, which are present at minute 68 and have a strong 50 kDa band.
( 3) 濃縮 (3) Concentration
(2) のステップで 52 kDa蛋白が含まれず、 50 kDa蛋白の含量が多か つた面分をブールし、 限外 ¾過膜 (FILTRON STRRED CELLS: フィルトロン,テク ノロジ一社製) で S縮した。 濃縮液 1 Om lの PA活性は 43000 I U/m 1 であり、 9 0 %の回収率が認められた。 また、 パス画分 52m lには 1 05 0 IU /m 1の PA活性が認められた。 In step (2), the area that does not contain the 52 kDa protein but has a high content of the 50 kDa protein is bulged, and is subjected to S-condensation using an ultrafiltration membrane (FILTRON STRRED CELLS: Filtron, Technology). did. The PA activity of 1 Oml of the concentrated solution was 43000 IU / m1, and a recovery of 90% was observed. In addition, PA activity of 105 IU / m1 was observed in 52 ml of the pass fraction.
各ステップ毎に蛋白量 (modified Lowry法、 Bensadoun A. & Weinstein D.: Anal. Biochem., 70, 241-250. 1976)、 PA活性、 比活性、 回収率、 精製度を求 めた (表 3) 。
For each step, the amount of protein (modified Lowry method, Bensadoun A. & Weinstein D .: Anal. Biochem., 70, 241-250. 1976), PA activity, specific activity, recovery, and purity were determined (Table 3)
¾3 ¾3
S C 0 ^ヽらのブロウ口キナーゼの職 容量 蛋白量 . Bacterial Kinase Protein Content of Blow-mouth Kinase of S C 0 ^ Pla.
雖 '縫 au¼) % `` Stitching sew au¼)
(ml) C^gmD-Ong) CIU/nil)-(IUxi03) (ml) C ^ gmD-Ong ) CIU / nil) - (IUxi0 3)
2870 386 · 1108 335 · 961 975 100 1.0 2870 3861108 335961 975 100 1.0
フ ΐ/Η:フ τπ-ス Ϊ́ / Η: τπ-
3640 260 · 946 265 · 965 1020 丄 UU 丄.1 3640 260 · 946 265 · 965 1020 丄 UU 丄 .1
600 19 - 11 1120 · 672 58947 70 60.5 600 19-11 1120 672 58 947 70 60.5
Sセフ了 n-ス S-sef n-s
1200 9 - 11 580 - 696 64444 72 66.1 i 62 56 · 3.5 7700 - 477 137500 50 141.0 1200 9-11 580-696 64 444 72 66.1 i 62 563.5 7700-477 137 500 50 141.0
10 284 · 8 43000 , 430 151408 45 155.0 10 2848 43000, 430 151 408 45 155.0
フュニルセファロ一スの溶出段階で蛋白 iは 1 %程度まで減少し、 精製度は 60 倍に上昇した。 さらに Sセファロースの溶出段階で、 精製度は 1 4 1倍まで上昇 し、 最後の濃縮液では P A活性が 4. 3 X 1 0s I U、 蛋白量が 2. 8mg、 比 活性が 1. 5 X 1 05 I UZmg、 回収率 4 5%、 精製度が 1 55倍であった。 In the elution stage of Funil Sepharose, protein i was reduced to about 1%, and the purity was increased 60-fold. Furthermore, in the S-Sepharose elution stage, the degree of purification increased to 141 times, and the final concentrate had a PA activity of 4.3 X 10 s IU, a protein amount of 2.8 mg, and a specific activity of 1.5 X 1 0 5 I UZmg, recovery 4 5%, degree of purification was 1 55 times.
(4) 得られたブロウ口キナーゼの性状の確認 (4) Confirmation of the properties of the obtained blow mouth kinase
得られた精製プロゥロキナーゼの酵素的性状を確認するために Km値を求め、 人胥細胞により産生された天然のブロウ口キナーゼ (以下、 トロンボリーゼとい う。 ) の Km値と比較した。 その結果、 合成基質 S— 2444 (発色合成試薬、 Kabi-Vitrium社製) に対する Km値はトロンボリーゼで 69 ^M. 本発明のプロ ゥロキナーゼで 75 / Mとほぼ同一の結果が得られた。 また、 ブラスミンによる
ブロウ口キナーゼの活性下の経時的変化もトロンボリーゼの場合と比べて大きな 差はなかった。 To confirm the enzymatic properties of the obtained purified properokinase, the Km value was determined and compared with the Km value of natural blow-mouth kinase (hereinafter, referred to as thrombolyse) produced by human Xu cells. As a result, the Km value for the synthetic substrate S-2444 (color-forming synthetic reagent, manufactured by Kabi-Vitrium) was 69 ^ M for thrombolyse, and almost the same as 75 / M for the prokinase of the present invention. Also by Brasmin The change over time under the activity of blow mouth kinase was not significantly different from that of thrombolyse.
さらに得られた精製ブロウ口キナーゼの N末端アミノ酸配列を決定した。 (3) で得られた S縮液 30 1に 2X BJ (Blue Juice: l O OmM Tr i s HC 1 ( H 6. 8) , 4 ¾SDS, 0. 2%ブロモフエノール ブルー, 20 グリセロール) を 30 // 1を加え、 95 'Cで 5分間加熱し、 SDS— PAGブ レート ( 1 0/20、 第一化学) に 1 5 /z 1づっ 4レーンにアブライし、 鬈気泳 動後、 PVDF膜に 7 OmAで一夜 4ででブロッテイングした。 ブロッテイング 緩衝液は 25mMトリス, 1 92mMグリシン, 20 %メタノールを使用した。 ブロッテイング後、 膜を蒸留水で 5分間 2回洗浄し、 クマーシー染色液 (0. 1 %CBB R— 250 i n 5 0 ½メタノール) 1 00 m 1に 1 0分間滇け、 脱色液 (50%メタノール、 1 0%醉酸) 80m 1で 5分間 3回脱色し、 さらに 蒸留水 1 0 Om lで 1 0分間、 6回洗浄した。 最後に 60%メタノールで 1回洗 浄し、 風乾した。 50 kD a付近のバンドを切り取り、 このペプチドの N末端ァ ミノ酸分析を行った。 この結果、 N末端アミノ酸配列は、 Further, the N-terminal amino acid sequence of the obtained purified blow-mouth kinase was determined. Add 2X BJ (Blue Juice: lO OmM Tris HC 1 (H6.8), 4¾SDS, 0.2% bromophenol blue, 20 glycerol) to the S condensate 301 obtained in (3) 30 / Add 1/1 and heat at 95'C for 5 minutes. Ablate SDS-PAG plate (10/20, Daiichi Kagaku) at 15 / z 1 in 4 lanes. After swimming, PVDF membrane At 7 OmA for 4 nights. The blocking buffer used was 25 mM Tris, 192 mM glycine, and 20% methanol. After blotting, the membrane was washed twice with distilled water for 5 minutes. Coomassie staining solution (0.1% CBB R—250 in 50% methanol) was applied to 100 ml for 10 minutes, and the decolorizing solution (50% Methanol, 10% drunk acid) Decolorized 3 times with 80 ml for 5 minutes, and further washed 6 times with 10 Oml of distilled water for 10 minutes. Finally, it was washed once with 60% methanol and air-dried. The band around 50 kDa was cut out, and the N-terminal amino acid analysis of this peptide was performed. As a result, the N-terminal amino acid sequence
Ser-Asn-Glu-Leu-X-Gln-Val-Pro-Ser-Asn-Cys-Asp-Cys-Leu-Asn-Gly-Gly-Thr で あり、 ヒト肾細胞由来のブロウ口キナーゼの N末端アミノ酸配列と一致した。 ま た、 用いた発現ベクターはムコール ' レンニンのシグナル配列にブロウ口キナー ゼの c D N Aを接铙した態様のものであるが、 正常な位置でブロセッシングを受 けブロウ口キナーゼを産生することが確認された。 Ser-Asn-Glu-Leu-X-Gln-Val-Pro-Ser-Asn-Cys-Asp-Cys-Leu-Asn-Gly-Gly-Thr Sequence matched. In addition, the expression vector used was a form in which cDNA of blow mouth kinase was ligated to the signal sequence of mucor 'rennin, but it was confirmed that it was processed at a normal position to produce blow mouth kinase. Was done.
実験例 1 培地中の各添加物の影響 Experimental example 1 Effect of each additive in the medium
培地中の各添加物のブロウ口キナーゼ產生等に対する影饗をみるために、 YP M2 培地 ( 1 %酵母抽出物、 2%パクトペプトン、 2%メタノール) の各添加物 を添加した 5種類のメタノール培地を調製した In order to see the effect of each additive in the culture medium on the growth of the blow-mouth kinase, etc., five kinds of YPM 2 medium (1% yeast extract, 2% pactopeptone, 2% methanol) were added. Prepared methanol medium
培地 1 肌 Medium 1 skin
培地 2 YP 2 +0.01¾ トライトン X-100 Medium 2 YP 2 + 0.01¾ Triton X-100
培地 3 YPM2 +0.1M アルギニン塩酸塩 Medium 3 YPM 2 + 0.1M arginine hydrochloride
培地 4 YPM2 +2¾ (NH4)2HP04 +2¾ NH4H2PO4
培地 5 : YPM2 +0.01¾ トライ トン X-100 +0.1M 了ルギニン塩酸塩 Medium 4 YPM 2 + 2¾ (NH 4 ) 2 HP0 4 + 2¾ NH4H2PO4 Medium 5: YPM 2 + 0.01¾ Triton X-100 + 0.1M Luginin hydrochloride
2¾ (ΝΗ«)2ΗΡ04 + 2¾ Η4Η2Ρ04 2¾ (ΝΗ «) 2 ΗΡ04 + 2¾ Η4Η 2 Ρ04
実施例 1〜2で得られたブロウ口キナーゼ分泌発現株 S C 06を YPD培地で 3 0て、 2日間 2回植え継ぎながら培養し、 30 0 m 1容のフラスコにいれた上 記 5種類 (培地 1〜培地 5) のメタノール培地 50m 1に 540 nmの吸光度 (As<。 ) が 0. 1 となるように植菌し (n = 3) 、 3 O'Cで 7日間培養した。 The blow-mouth kinase secretion-expressing strain SC06 obtained in Examples 1 and 2 was cultured in YPD medium for 30 days, subcultured twice for 2 days, and placed in a 300-ml 1-volume flask. The medium 1 to 5) was inoculated into 50 ml of a methanol medium so that the absorbance (A s < .
24時間毎にサンプリングを行い、 Ae*。 測定、 PA活性測定、 抗 UK抗体によ るウエスタンプロットを行った。 菌体の増殖曲線を図 5に示す。 Sampling every 24 hours, A e *. Measurement, PA activity measurement, and Western plot with anti-UK antibody were performed. Fig. 5 shows the cell growth curve.
培地 1 と培地 2はほぼ同じ曲線を示し、 2曰目で A"。 が 2 1〜23になり、 その後渐減した。 培地 3では 3日目では 4 1. 4まで上昇し、 その後渐減した。 培地 4と培地 5では 1日目の墦殖は非常に遅かったが、 その後増殖速度が早くな り、 培地 4では 4日目に 36. 4、 培地 5では 42. 1まで増加し、 その後渐減 した。 Medium 1 and Medium 2 showed almost the same curve, and A "was changed from 2" to 2 to 23, and then decreased. Medium 3 increased to 41.4 on day 3 and then decreased. The growth on day 1 was very slow in medium 4 and medium 5, but the growth rate then increased, increasing to 36.4 on day 4 in medium 4 and 42.1 in medium 5. Since then, it has decreased.
フイブリンブレート法による P A活性を図 6に示す。 FIG. 6 shows the PA activity by the fibrin plate method.
培地 1では 3日目で 7 1 IU/mlまで上界し、 その後減少したが、 培地 2で は 3倍以上、 培地 3では約 4倍の活性上昇が認められた。 培地 4では培地 2より も低く、 約 2倍程度であった。 全ての添加物を加えた培地 5では活性が著しく上 昇し、 5日目では 867 I U/m lであった。 On day 3, medium 1 showed an upper bound of 71 IU / ml, and then decreased. Medium 4 was lower than medium 2 and about twice as high. In the medium 5 to which all additives were added, the activity was remarkably increased, and was 867 IU / ml on the fifth day.
2日目から 6日目までの培養上淸をゥエスタンプロットにより経時的に観察し た。 培地 1では P A活性が出現した 2日目ですでに完全型ブロウ口キナーゼの 50 kDaバンドはほとんど認められず、 33 kDaと 29 kDaのバンドが主であ り、 その後 33 kDaバンドは減少し、 29 kDaバンドのみが残った。 培地 2 の場合も培地 1 と同様の傾向であった。 培地 3では 2日目で 50 kDaと 4 7 k Daのバンドが等量存在し、 3日目で 5 O kD aバンドが減少し、 5日目以降 50 kDa、 47 kDaバンドが消失し、 29 k D aから 35 k D aの分解物が增加 した。 培地 4では 3日目までは 50 kDaバンドが主であつたが、 その後減少し た。 しかし、 培地 3のような 29 kDaから 35 k D aの分解物は少なかった。 培地 5では 6日目まで 50 kDaのバンドが主で分解物は少なかった。
これらの結果から 0. 0 1 κトライトン X— 1 00の添加は、 菌の增殖やブロ ゥロキナーゼの低分子化抑制には影 Sしないが、 Ρ Α活性は 3倍以上增加してお り、 ブロウ口キナーゼのフラスコへの吸着を著しく抑えているものと予想される e The culture supernatant from day 2 to day 6 was observed over time using a ゥ stamp lot. On the second day when PA activity appeared in Medium 1, almost no 50 kDa band of complete blown-mouth kinase was recognized, and the 33 kDa and 29 kDa bands were predominant, followed by a decrease in the 33 kDa band. Only the 29 kDa band remained. In the case of medium 2, the tendency was similar to that of medium 1. In medium 3, 50 kDa and 47 kDa bands were present in equal amounts on the second day, the 50 kDa band decreased on the third day, and the 50 kDa and 47 kDa bands disappeared from the fifth day onward. A degradation product of 35 kDa from kDa was added. In Medium 4, the 50 kDa band was predominant until day 3, but then decreased. However, the amount of degradation products from 29 kDa to 35 kDa as in the medium 3 was small. In the medium 5, up to the sixth day, the band of 50 kDa was mainly contained, and the amount of degradation products was small. From these results, it was found that the addition of 0.01 kappa Triton X-100 did not affect bacterial growth or suppress the molecular weight of prokinase, but the activity was increased by more than 3 times. e which is expected to have significantly suppressed adsorption to the flask mouth kinase
0. 1 Mアルギニンの添加では菌の增殖を 2倍程度促進し、 中程度の低分子化 抑制効果を示した。 リン酸アンモニゥムの添加は菌の增殖を 1. 5〜2倍程度促 進し、 3曰目までは低分子化を著しく抑制した。 トライトン X— 1 00、 アルギ ニンおよびリン酸アンモニゥムを添加した場合、 各添加物の相乗効果が認められ、 ?八活性が ^: 培地で培養したときの約 1 0倍まで上昇し、 低分子化も著し く抑制された。 Addition of 0.1 M arginine promoted the growth of the bacterium about twice, and showed a moderate inhibitory effect on low molecular weight. Addition of ammonium phosphate promoted the growth of the bacteria about 1.5 to 2 times, and significantly suppressed the low molecular weight up to the third point. When Triton X-100, arginine and ammonium phosphate were added, a synergistic effect of each additive was observed. Eight activities increased to about 10-fold when cultured in the ^: culture medium, and low molecular weight was also significantly suppressed.
実験例 2 培地への非イオン性界面活性剤及びアミノ酸添加の影謇 Experimental Example 2 Addition of nonionic surfactant and amino acid to medium
実施例 1〜2で調製したブロウ口キナーゼ分泌発現株 SC 06を YPD培地 (1 %酵母抽出物、 2%バクトペプトン、 2%グルコース) で 30て、 一夜培養 した。 その後、 " が 0. 1の S度となるように 300m 1容フラスコに入つ た表 4記載の培地各々 30mlに植菌し、 30 'Cで 72時間と 1 44時間培養し た培養液の A,«。 と PA活性を ISベた (表 4) 。 なお、 以下の表中で Arg はアル ギニン塩酸塩を、 Glutamate はグル夕ミン酸ナトリゥムを示す。 Blow-mouth kinase secretion-expressing strain SC06 prepared in Examples 1-2 was cultured overnight in YPD medium (1% yeast extract, 2% bactopeptone, 2% glucose) for 30 days. Then, inoculate 30 ml of each of the culture media listed in Table 4 in a 300-ml one-volume flask so that the "" becomes 0.1 degree of S. The culture solution was cultured at 30'C for 72 hours and 144 hours. A, «, and PA activity were measured (Table 4) In the following table, Arg indicates arginine hydrochloride, and Glutamate indicates sodium glutamate.
¾4 トライトン X— 100およ DfTルギニン翻 HDi^g (卩八活性ノ八,*0) 培 地 i2m mm ¾4 Triton X-100 and DfT Luginin Verification HDi ^ g (Jihachihachi * 8, * 0 ) Medium i2m mm
(讓 /A,") (讓 /As") (Care / A, ") (Care / A s ")
28/1 3 13/1 7 28/1 3 13/1 7
mi2+0.01%TritODX-100 130/14.5 115/11.5 mi 2 + 0.01% TritODX-100 130 / 14.5 115 / 11.5
m+ClMArg 45/26.1 12/18.4 m + ClMArg 45 / 26.1 12 / 18.4
YPUj+0.01¾ TritonX-100 +0.1 Arg 310/2 5 380/16.8
0. 0 1 %トライトン X— 1 30添加培地を用いた 72時間培養では、 基本培 地での場合と増殖度は同じであつたが、 P A活性は基本培地の 4. 6倍であった。 また、 0.1 Mアルギニン添加培地では増殖が亢進し、 PA活性は基本培地の 1.6 倍であり、 0. 0 1 %トライトン X— 1 00 + 0. 1 Mアルギニン添加培地では PA活性は、 基本培地の 1 1倍に上昇した。 YPUj + 0.01¾ TritonX-100 +0.1 Arg 310/2 5 380 / 16.8 In the 72-hour culture using the medium containing 0.01% Triton X-130, the degree of growth was the same as that in the basal medium, but the PA activity was 4.6 times that of the basal medium. In the medium supplemented with 0.1 M arginine, the proliferation was enhanced, the PA activity was 1.6 times that of the basal medium, and in the medium supplemented with 0.1% Triton X-100 + 0.1 M arginine, the PA activity was increased in the basal medium. 1 rose 1 times.
1 44時間培養後の PA活性は基本培地、 0. 0 1 %トライトン X- 1 0 0添 加培地、 0. 1 M アルギニン添加培地では 72時間培養後のものと比較して低 下傾向であつたが、 0. 0 1 %トライトン X— 1 00十 0. 1Mアルギニン添加 培地では渐增していた。 After 44 hours of culture, the PA activity of basal medium, medium supplemented with 0.1% Triton X-1000, and medium supplemented with 0.1 M arginine tended to decrease compared to that after culture for 72 hours. However, it was poor in the medium containing 0.01% Triton X-100 and 0.1M arginine.
次にこれらの培養上清について抗 UK抗体によるウエスタンブロットを行った c 72時間培養の基本培地では 30 k D a以下の分解物のみが認められ、 トライト ン X— 1 0 0添加では 47 kDa、 アルギニン添加では 50 kDaのうすいバン ドが認められた。 トライトン X— 1 00+アルギニン添加では 5 O kD aと 4 7 kDaの濃いバンドが存在していた。 Next, these culture supernatants were subjected to Western blotting using an anti-UK antibody.c. Only a degradation product of 30 kDa or less was observed in the basal medium cultured for 72 hours, and 47 kDa was added when Triton X-100 was added. With the addition of arginine, a light band of 50 kDa was observed. When Triton X-100 and arginine were added, dark bands of 50 kDa and 47 kDa were present.
実験例 3 培地へのリン酸塩およびアンモニゥム塩添加の影響 Experimental Example 3 Effect of adding phosphate and ammonium salt to the culture medium
SC 0 6株を YPD培地に 3 O'Cで一夜培養後、 A"。 が 0. 1の S度になる ように 300m l容フラスコに表 5に記載の各培地 30m lに植菌し、 30でで 6 5時間培養した (表 5〉。
After culturing SC06 strain in YPD medium overnight at 3 O'C, inoculate 30 ml of each medium described in Table 5 in a 300 ml flask so that A "is 0.1 S degree. The cells were cultured at 30 for 65 hours (Table 5).
表 5 Table 5
リン酸アンモニゥム添加の影譽 Recognition of adding ammonium phosphate
I <口 1 U/ tillノ A n n I <Mouth 1 U / till no A n n
基本培地 5 9 1 3. 2 Basic medium 5 9 1 3.2
培地 1 6 1 1 6. 4 Medium 1 6 1 1 6.4
培地 2 1 28 1 5. 6 Medium 2 1 28 1 5.6
培地 3 1 54 1 7. 6 Medium 3 1 54 1 7.6
培地 4 1 76 1 7. 9 基本培地 : YP 2 Medium 4 1 76 1 7.9 Basic medium: YP 2
培地 1 : ΥΡΜ2 +1¾ Η*Η2Ρ0« +1¾ (NHJ2HP04 Medium 1: ΥΡΜ 2 + 1¾ Η * Η 2 Ρ0 «+ 1¾ (NHJ 2 HP0 4
培地 2 : YP 2 十 0.67¾ NH4H2P04十 1.33% (NH4)2HP0* Medium 2: YP 2 tens 0.67¾ NH 4 H 2 P0 4 Ten 1.33% (NH 4) 2 HP0 *
培地 3 : YPM2 +2¾ NH4H2P0« 十 2¾ (NH aHPO* Medium 3: YPM 2 + 2¾ NH4H 2 P0 «12¾ (NH aHPO *
培地 4 : YPM2 +1.33¾ NH*H2P0*+2.67¾ ( H4)2HP0« Medium 4: YPM 2 + 1.33¾ NH * H 2 P0 * + 2.67¾ (H 4 ) 2 HP0 «
1 %NH4 H2 P04 + 1 % (NH4 ) 2 HPO4 添加培地では YPM2 基本 培地と PA活性は同じであつたが、 0. 67%NH4 H2 PO* + 1. 3 3% ( H4)2HP04添加培地では約 2倍の活性上昇を示した。 また、 2½NH« H2 PO, + 2 (NH4 ) 2 HP04 添加培地と 1. 33%NH< H2 PO« +2. 67 % (NH4 ) 2 HPO* 添加培地では約 3倍の活性上昇が認められた。 一方、 (NH* ) 2 HPO* 単独添加では 2¾、 4 %ともに増殖を抑制し、 かつ PA活 性も認められなかった。 1% NH 4 H 2 P0 4 + 1% (NH 4) 2 HPO4 is been made the same as YPM 2 basal medium and PA activity in supplemented medium, 0. 67% NH 4 H 2 PO * + 1. 3 3% (H 4) is a 2 HP0 4 added medium showed activity increase of about 2-fold. Further, 2½NH «H 2 PO, + 2 (NH 4) 2 HP0 4 added medium and 1. 33% NH <H 2 PO « +2. 67% (NH 4) 2 HPO * In addition medium of about 3 times the activity A rise was noted. On the other hand, when (NH *) 2 HPO * alone was added, growth was inhibited at both 2% and 4%, and no PA activity was observed.
実験例 4 培地への非イオン性界面活性剤、 アミノ酸、 リン酸塩およびアンモニ ゥム塩添加の影響 Experimental Example 4 Effect of adding nonionic surfactant, amino acid, phosphate and ammonium salt to the culture medium
同様にして、 基本培地にトライトン X— 1 00、 アルギニン、 リン酸埴及びァ
ンモニゥム塩添加を添加して菌体の増殖および P A活性への影響を調べた < Similarly, add Triton X-100, Arginine, Phosphoric Acid Effect of addition of ammonium salt on cell growth and PA activity was examined <
表 6 トライトン X— 100, アブ ニン, リン酸アンモニゥム¾¾«10¾# 培地 PAS¾(IU/ml) \540 地 62 11. 9 Table 6 Triton X-100, abnin, ammonium phosphate (10%) # medium PAS (IU / ml) \ 540 Ground 62 11.9
培地 1 110 16. 8 Medium 1 110 16.8
培地 2 620 22. 8 Medium 2 620 22.8
培地 3 870 28. 9 Medium 3 870 28. 9
: YPM2 : YPM 2
培地 2: YPM2 +0.01% TritonX-100 + 0.1M Arg Medium 2: YPM 2 + 0.01% TritonX-100 + 0.1M Arg
培地 3: YP 2+2¾ NH4HzP04+2¾(H4)2HP04+0.01¾rritonX-100+0.1M Arg Medium 3: YP 2 + 2¾ NH4HzP04 + 2¾ (H4) 2HP04 + 0.01¾rritonX-100 + 0.1M Arg
表 6から、 トライトン X— 1 0 0 +アルギニン添加培地に比べ、 さらに 2% NH4 H2 PO* + 2% (NH4 ) 2 HPO4 を添加した場合には増殖が促進さ れ、 PA活性もさらに 1. 4倍上昇した。 この培養上淸の抗 UK抗体によるゥェ スタンプロットを行った。 YPM2 培地では 50 kDaバンドはなかったが、 4 %リン¾アンモニゥム添加では 5 0 kDaバンドが認められた。 トライトン X— 1 00÷ァルギニン添加では 5 0 kDaと 47 kDaのバンドがあり、 47 kDa の方が濃かったが、 さらに 4%リン酸アンモニゥムを添加した場合には 5 0 kDa バンドが主であり、 47 kDaバンドは少なかった。 この結果から、 4%リン酸 アンモニゥム添加は 5 0 kDaから 47 kD aへの蛋白質の低分子化を抑制して いるものと考えられた (図 7) 。 Table 6 shows that when 2% NH 4 H 2 PO * + 2% (NH 4 ) 2 HPO4 was added, the growth was promoted and the PA activity was higher than that of the Triton X-100 + arginine supplemented medium. It also rose 1.4 times. A stamp lot using the anti-UK antibody on this culture was performed. In YPM 2 medium was not 50 kDa band, but 5 0 kDa band was observed in 4% phosphate ¾ Anmoniumu added. When Triton X-100 arginine was added, there were bands at 50 kDa and 47 kDa, and the band at 47 kDa was deeper, but when 4% ammonium phosphate was added, the band at 50 kDa was predominant. The 47 kDa band was few. From these results, it was considered that the addition of 4% ammonium phosphate suppressed the reduction of the protein from 50 kDa to 47 kDa (Fig. 7).
実験例 5 培地へのグルタミン酸、 ベンズアミジン、 アブロチニン、 カゼイン
水解物 (カザミノ酸、 NZ—ァミン、 NZ— C a s e) 、 アンモニゥム塩、 リン 酸塩添加の彩響 Experimental Example 5 Glutamic acid, benzamidine, abrotinin, casein Hydrolyzate (casamino acid, NZ-amine, NZ-Case), ammonium salt, and the addition of phosphate
実験例 3で効果のあったリン酸アンモニゥムについて、 リン酸塩に効果がある のか、 アンモニゥム塩の効果があるのか知るために、 NH* C 1と Na— PC の影響を調べた。 また、 YPM2 に 0. 0 1 %トライトン X— 1 00を加えた培 地を基本培地とし、 それに各化合物を添加して菌体の增¾およびブ πゥロキナー セ'産生の影響を調べた。 The effects of NH * C1 and Na-PC were investigated to determine whether ammonium phosphate, which was effective in Experimental Example 3, had an effect on phosphate or an ammonium salt. Further, a basic medium culture locations plus 0.0 1% Triton X- 1 00 in YPM 2, it was investigated the effect of增¾ and blanking π Urokina Se 'production of cells by adding the compound.
SC O 6を YPD培地で一夜培養後、 A^n が 0. 1の jg度になるように各培 ¾5m 1 Zチューブに植菌し、 3 O'Cで 70時間培巷した。 結果を表 7に示す。
After culturing SCO 6 overnight in YPD medium, the cells were inoculated into 5 ml 1 Z tubes for each culture so that A ^ n was 0.1 jg, and cultured in 3 O'C for 70 hours. Table 7 shows the results.
アルギニン, グルタミン酸 ベン; 7ミジン, アブロチニン, カゼイン水解物, アンモニゥ Λ¾ ';
(PA活性ノ AS") Arginine, ben-glutamate; 7-midine, abrotinin, casein hydrolyzate, ammonia (PA activity Roh A S ")
IU/ml/A 540 IU / ml / A 540
1 YP 2+0.01¾ Tri ton X-100 50/12· 61 YP 2 + 0.01¾ Tri ton X-100 50/12
2 YP2+0.01% Tri ton X-100+0.1M Arg 125/23.02 YP 2 + 0.01% Tri ton X-100 + 0.1M Arg 125 / 23.0
3 YPM2+0.01% Triton X-100+0.1M Glutanate 215/25.93 YPM 2 + 0.01% Triton X-100 + 0.1M Glutanate 215 / 25.9
4 Ρ ι+0.01¾ Triton X-100+ Benzamidine 35/13.54 Ρ ι + 0.01¾ Triton X-100 + Benzamidine 35 / 13.5
5 mia-H).01¾ Triton X-lOOlOaM Benzamidine 10/ 9.95 mia-H) .01¾ Triton X-lOOlOaM Benzamidine 10 / 9.9
6 YFM2+0.01¾ Triton Χ-100+lOlU/ml Aprotinin 56/13.26 YFM2 + 0.01¾ Triton Χ-100 + lOlU / ml Aprotinin 56 / 13.2
7 YPM2+0.01¾ Tri ton X-100+3¾ Casamino acid 410/41.87 YPM 2 + 0.01¾ Tri ton X-100 + 3¾ Casamino acid 410 / 41.8
8 YPMi-K).01% Tri ton X-10Of3¾ NZ-Amine 105/23.98 YPMi-K) .01% Tri ton X-10Of3¾ NZ-Amine 105 / 23.9
9 YPMj+0.01% Tri ton X-10M Z-Case 59/19.59 YPMj + 0.01% Tri ton X-10M Z-Case 59 / 19.5
10 ΥΡΜί+ΰ.01¾ Tri ton Χ-100+·細 ^ΡΟ,+Σ^ΟΪ ) 2HPO4 79/1 3 11 ΪΡΜ2+0.01% Triton X-lOOtmCl 11/ 3.610 ΥΡΜί + ΰ.01¾ Tri ton Χ-100 + ・ thin ^ ΡΟ, + Σ ^ ΟΪ) 2HPO4 79/1 3 11 ΪΡΜ 2 + 0.01% Triton X-lOOtmCl 11 / 3.6
12 ΪΡΜ2+0.01¾ Triton X-100+0.25M Na-P04(pH6.0) 2/20.412 ΪΡΜ2 + 0.01¾ Triton X-100 + 0.25M Na-P0 4 (pH6.0) 2 / 20.4
13 YPM2-K).01¾ Triton X-100+0.25M a-P (pi .O) 4/17.913 YPM 2 -K) .01¾ Triton X-100 + 0.25M aP (pi .O) 4 / 17.9
14 YPM2+0.01¾ Tri ton X-100+0.25M Na-P04 CpiTT.5) 41/19.2 14 YPM 2 + 0.01¾ Tri ton X -100 + 0.25M Na-P0 4 CpiTT.5) 41 / 19.2
30eC70 hrs.5nil/tube culture 30 e C70 hrs.5nil / tube culture
PA活性は 0. IN!グルタミン酸添加では基本培地の 4. 3倍に上昇し、 0.1 Mアルギニン添加よりも効果的であった。 lmM, 1 OmMのベンズ了ミジン添 加では P A活性は低下した。 10 IU/mlアブロチニンは PA活性に影響しな かった。 また、 カゼイン水解物のうち 3%カザミノ酸が菌体の増殖を促進し、 基
本培地の約 8倍の PA活性の上昇が認められた。 また、 4 ½NH4 C 1は菌体増 殖およびブロウ口キナーゼの産生量を抑制した。 0. 25M Na— P04 添加 では pH 7. 0以下では增¾は促進しているのもかかわらず PA活性は低かった c これらの培養上淸の抗 UK抗体によるウェスタンプロットを行った。 The PA activity was increased 4.3 times with the addition of 0.1 IN! Glutamic acid compared to the basal medium, and was more effective than with the addition of 0.1 M arginine. Addition of benzyl-midine at lmM or 1 OmM reduced PA activity. 10 IU / ml abrotinin did not affect PA activity. In addition, 3% casamino acid of the casein hydrolyzate promotes cell growth, An increase in PA activity about 8 times that of this medium was observed. In addition, 4 CNH 4 C 1 suppressed cell growth and production of blow-mouth kinase. 0. 25M Na-P0 4 at pH 7. 0 or less in addition增¾ were subjected to Western plot also by PA activity was low c anti UK antibody on these culture cleanse regardless're promoted.
グルタミン酸、 ベンズアミジンおよびアブロチニン添加では 50 kD aバンド が主で、 47 kDaバンドは少なかった。 3%カザミノ酸では 5 O kDaと 4 7 kDaバンドが同程度存在していた。 4¾NH« C 1では 50 kD aバンドのみ が認められ 30 kD a以下の分解物もほとんどなかった。 0.25M Na-PO« 添加では pH7. 5の培養条件では 5 O kDaバンドの下に 47 kDaのうすい バンドが認められた。 Addition of glutamic acid, benzamidine and abrotinin resulted in a predominantly 50 kDa band and a small 47 kDa band. In 3% casamino acid, 5 O kDa and 47 kDa bands were present to the same extent. At 4¾NH «C1, only a 50 kDa band was observed, and almost no degradation products of 30 kDa or less were observed. With the addition of 0.25 M Na-PO, a 47 kDa light band was observed under the 50 kDa band under the culture condition of pH 7.5.
これらの結果からアンモニゥム塩に 50 kDa蛋白の低分子化を著しく抑制す る効果が有ると認められる。 From these results, it is recognized that ammonium salt has an effect of remarkably suppressing the reduction of the molecular weight of the 50 kDa protein.
次に、 上記の実験で効果のあったカザミノ酸、 グルタミン酸、 アブロチニン、 ベンズアミジンの添加実験を行った。 結果を表 8に示す。
Next, experiments were conducted in which casamino acid, glutamic acid, abrotinin, and benzamidine, which were effective in the above experiment, were added. Table 8 shows the results.
表 8 カザミノ グルタミン酸 アブロチニン,' ベン ミジン. リン si Table 8 Casamino glutamate abrotinin, 'benmidine. Phosphorus si
ma<D - (? 活性 八,") ma <D-(? Active eight, ")
IU/ml/A 540 IU / ml / A 540
1 YPM2+0.01¾ Tri ton X-100 63/13.41 YPM2 + 0.01¾ Tri ton X-100 63 / 13.4
2 01¾ Tri ton X-100+2¾ Casamino acid 510/35.72 01¾ Tri ton X-100 + 2¾ Casamino acid 510 / 35.7
3 YP 2-K).01¾ Triton X-1003¾ Casamino acid 490/42.33 YP 2 -K) .01 Triton X-1003 Casamino acid 490 / 42.3
4 YP a+0.01¾ Triton X-100+4¾ Casamino acid 370/43.94 YP a + 0.01¾ Triton X-100 + 4¾ Casamino acid 370 / 43.9
5 YPM2+0.01¾ Triton X-10(H5¾ Casamino acid 265/45.05 YPM2 + 0.01¾ Triton X-10 (H5¾ Casamino acid 265 / 45.0
6 YPMz-Kl.01¾ Triton X-100+3¾ Casamino acid+0.1M Glutamte 510/43.56 YPMz-Kl.01¾ Triton X-100 + 3¾ Casamino acid + 0.1M Glutamte 510 / 43.5
7 YPMz+0.01¾ Triton X-10(H3¾ Casamino acidflOIU/ml Aprotinin 560/4 67 YPMz + 0.01¾ Triton X-10 (H3¾ Casamino acidflOIU / ml Aprotinin 560/4 6
8 YP 2+0.01¾ Tri ton X-10(H3¾ Casamino acid+ Benzamidine 470/38.7 8 YP 2 + 0.01¾ Tri ton X-10 (H3¾ Casamino acid + Benzamidine 470 / 38.7
30 *C,71 hrs.5ml/tube culture 30 * C, 71 hrs.5ml / tube culture
30'C、 7 1時間塔養でカザミノ酸の濃度を 2%から 5%に変えた場合、 PA 活性は 2〜 3 %では、 約 500 I U/m 1であつたが、 4 %以上では低下の傾向 であった。 また、 3%カザミノ酸に 0. 1Mグルタミン酸、 1 0 I U/m lアブ ロチニン、 ImMベンズアミジンを添加した場合、 PA活性は 3½カザミノ酸と 同程度であった。 これらの培養上淸の抗 UK抗体によるウェスタンブロッ トを行 つた。 2%から 5%カザミノ酸添加ではカザミノ酸の農度が高いほど、 多少分解 は少なかったが、 5 O kDaと 4 7 kD aのバンドはほぼ同程度であった。 また、 3 %カザミノ酸にさらにグルタミン酸、 アブ口チュンまたはべンズァミジンを添 加した場合、 5 O kDaから 47 kD aの低分子化を抑制することはできなかつ
実験例 1から 5の結果から、 產生量を上げるにはトライトン X— 1 00、 アル ギニン、 グルタミン酸、 カザミノ酸が有効であり、 5 0 kDa蛋白から 4 7 kDa 蛋白の低分子化を防ぐためにはアンモニゥム塩、 特にリン酸アンモニゥムが効果 的であった。 When the casamino acid concentration was changed from 2% to 5% in 30'C, 7 hour column, PA activity was about 500 IU / m1 at 2-3%, but decreased at 4% or more. The trend was When 0.1 M glutamic acid, 10 IU / ml abrotinin and ImM benzamidine were added to 3% casamino acid, the PA activity was almost the same as that of 3-casamino acid. Western blots were performed with anti-UK antibodies on these cultures. With the addition of 2% to 5% casamino acid, the higher the agricultural level of casamino acid, the less the degradation was, but the bands at 50 kDa and 47 kDa were almost the same. In addition, when glutamic acid, abuchichun or benzamidine is further added to 3% casamino acid, it is not possible to suppress the reduction of the molecular weight from 50 kDa to 47 kDa. From the results of Experimental Examples 1 to 5, Triton X-100, arginine, glutamic acid, and casamino acid are effective for increasing the production amount.To prevent the 50 kDa protein to 47 kDa protein from becoming smaller, Ammonia salts, especially ammonium phosphate, were effective.
実験例 6 インビト口でのブロウ口午ナーゼの分解抑制実験 Experimental Example 6 Inhibition of Blown Meridase Degradation at Invitro
各添加物の分解抑制効果をみるために下記の実験を行った。 The following experiment was performed to see the decomposition inhibitory effect of each additive.
ビキア酵母 GTS 1 1 5株を YPM2 培地で 1 4 4時闉、 3 0eCで培養し、 得 られた培養物を 0. 22 mのフィルターで滤過して培養上淸とした。 該培養上 淸 3 0 1に表 9記載の各添加物 (合計 1 7. 5 D および実施例 3に従って SC O 6株の培養上清から精製したブロウ口キナーゼ (2. 5 u l ) を添加して 反応液 (5 0 ί】) とし、 シリコナイズしたコニカルチューブに入れて 3 0 で 24時間インキュベートし、 ブロウ αキナーゼの分解の程度をゥヱスタンブロッ トで謂べた。 なお、 各添加物の配合量の割合を表 9に示す。 Bikia yeast GTS 1 1 5 strain YPM 2 medium at 1 4 4 Toki闉, and cultured in 3 0 e C, and滤過the culture obtained in the filter of 0. 22 m was cultured on cleansed. To the culture medium 301, added were each of the additives described in Table 9 (total 17.5 D and blow-mouth kinase (2.5 ul) purified from the culture supernatant of the SCO 6 strain according to Example 3). The reaction solution (50ί) was placed in a siliconized conical tube, incubated at 30 for 24 hours, and the degree of decomposition of Blow α-kinase was so-called “stan-blot”. Is shown in Table 9.
表 9 Table 9
1 2 3 4 5 control culture sup. SO 30 30 30 30 30CYPM2)1 2 3 4 5 control culture sup.SO 30 30 30 30 30 CYPM2)
0.1¾ Triton X-100 0 5 0 0 5 0 0.1¾ Triton X-100 0 5 0 0 5 0
2Μ Arg. 0 0 2.5 0 2.5 0 2Μ Arg. 0 0 2.5 0 2.5 0
20%腸 2Ρ04 0 0 0 5 5 0 20% intestine 2 Ρ0 4 0 0 0 5 5 0
Η20 17.5 1Z5 15 7.5 0 17.5 Η 2 0 17.5 1Z5 15 7.5 0 17.5
ProU 2.5 5 5 5 2.5 2.5 ProU 2.5 5 5 5 2.5 2.5
50 50 50 50 50 50 ul
その結果、 0. 0 1 ¾トライトン X— 1 00の添加では、 分解の伏 ¾は添加物 無添加と同程度であった。 0. 1Mアルギニン添加では 35 kD a以下の分解物 は少なかったが、 47 kD aの分解物がやや見られた。 リン酸アンモニゥム添加、 またはトライトン X— 1 00、 アルギニンとリン酸アンモニゥムの添加では分解 はかなり抑制されていた。 50 50 50 50 50 50 ul As a result, with the addition of 0.01% Triton X-100, the degree of decomposition was almost the same as with no additive. When 0.1M arginine was added, the amount of degraded products of 35 kDa or less was small, but the amount of degraded products of 47 kDa was slightly observed. Addition of ammonium phosphate, or Triton X-100, arginine and ammonium phosphate, significantly inhibited degradation.
実験例 7 分解産物の N末端ァミノ酸配列 Experimental example 7 N-terminal amino acid sequence of degradation product
SC O 6株を添加物無添加の YPM2 培地で培養すると、 完全体のブロウロキ ナーゼは PA活性が認められた 2日めで既にほとんど存在せず、 短時間で 3 O k Da蛋白 (非還元条件) に分解した。 この分解物の構造を調べるために下記の実 験 ¾:行つに0 When cultured in YPM 2 medium additives without addition of SC O 6 strain Burouroki kinase full body not already almost present in second day was observed PA activity in a short time 3 O k Da protein (non-reducing conditions ). In order to investigate the structure of this degradation product, the following experiment was performed.
S C 0 6株を YPM2 培地 50m 1に ( 30 0 m 1容フラスコ) 植菌して、 30 'Cで 5日間培養し、 その培養液 30 0 m 1に 1 M トリス塩酸 (pH7.5 ) 1 6 m l、 1 %トライトン X— 1 00 3. 2m 1を添加し、 塩酸で pH7. 5に謂 整後、 抗ゥロキナーゼ抗体ホルミルーセル口ファインカラム (日本チッツ社製) に供して、 平衡化用緩衝液 〔5 OmMトリス塩酸 (PH7. 5) 、 0. 0 1 %ト ライトン X— 1 0 0〕 で洗浄後、 さらに緩衝液 〔5 OmMトリス塩酸 (pH 7. 5) 、 0. 5M Na C 0. 0 1 ½トライトン X— 1 00〕 で洗浄し、 溶出 液 〔0. 2M グリシン塩酸 (pH 2. 5) 、 0. 5M NaC l、 0. 0 1 % トライトン X— I 0 0〕 で溶出した。 P A活性のある溶出液をモルカツト L (分 画分子量 10000、 UFP2LGC24、 ミリボア社製) およびウルトラフリー C 3— L G C (分面分子量 10000 、 ミリポア社製) で約 100倍に濃縮したこのサンブルを S DS-PAGEにかけて 30 kDaのバンドを切り出して、 そこから抽出して得 られた 3 0 kD a蛋白質のァミノ酸配列を決定した。 SC 0 6 strain YPM 2 medium 50m 1 (30 0 m 1 flask) was inoculated, 30 'and cultured for 5 days at C, and the culture liquid 30 0 m 1 1 M Tris-HCl (pH 7.5) Add 16 ml, 1% Triton X-100 3.2 ml, adjust the pH to 7.5 with hydrochloric acid, and apply to an anti-perokinase antibody formyl-cell mouth fine column (manufactured by Nippon Chitz) to equilibrate the buffer. After washing with the solution [5 OmM Tris-HCl (PH7.5), 0.01% Triton X—100], the buffer [5 OmM Tris-HCl (pH7.5), 0.5M NaC0 0.1 Triton X-100] and eluted with an eluent [0.2M glycine hydrochloride (pH 2.5), 0.5M NaCl, 0.01% Triton X-I 00]. . The eluate with PA activity was concentrated approximately 100-fold with molcut L (fraction molecular weight 10,000, UFP2LGC24, manufactured by Miriboa) and Ultra-free C3-LGC (fraction molecular weight 10,000, manufactured by Millipore). The band of 30 kDa was cut out by -PAGE, and the amino acid sequence of the 30 kDa protein obtained by extracting from the band was determined.
その結果、 下記のァミノ酸配列を N末端に有する 2本のピークが認められた。 As a result, two peaks having the following amino acid sequence at the N-terminus were observed.
① Ile-Ile-Gly-Gly-Glu-Phe-Thr-Thr-Ile-Glu-Asn-Gln-① Ile-Ile-Gly-Gly-Glu-Phe-Thr-Thr-Ile-Glu-Asn-Gln-
② Ly s-Pro-Ser-Ser-Pr o-Pro-Gl u-Gl u-Leu-Lys-Phe-② Lys-Pro-Ser-Ser-Pro-Pro-Glu-Glu-Leu-Lys-Phe-
①のアミノ酸配列はブロウ口キナーゼの N末端から 1 5 9番目のイソロイシンか らの配列に一致し、 ②のアミノ酸配列はブロウ口キナーゼの N末端から 1 3 6番
目のリジンからの配列に一致した。 このことから、 30 kDa蛋白質は低分子 2 本鎖夕イブのゥロキナーゼであると考えられた。 The amino acid sequence of ① matches the sequence from the isoleucine at the 159th position from the N-terminal of the blow-mouth kinase, and the amino acid sequence of ② is 1336 from the N-terminal of the blow-mouth kinase. It matched the sequence from the lysine of the eye. This suggests that the 30 kDa protein is a small double-stranded perovin kinase.
参考例 P A活性の測定 Reference example Measurement of PA activity
PA活性は、 Levin. E. G..らの方法 (フイブリンプレート法、 J. Cell Bio., 94, 631-636. 1982 ) に従って測定した。 PA activity was measured according to the method of Levin. E. G .. et al. (Fibrin plate method, J. Cell Bio., 94, 631-636. 1982).
6 O'Cの 1 %寒天溶液に 1 0 0 1 U/m 1のヒトトロンビンを 1ノ 50量加え た後、 すぐに 50mMリン酸ナトリゥム锾衝液 (PH7.0 )、 100 mM Na C 1、 0. 1 ¾NaN3 中に 1 ¾ゥシフイブリノ一ゲンを溶解した 37'Cの溶液を等量 混合し、 水平なプレートに添加し、 寒天を固化させる。 固化した白濁の寒天層に 直径 4 mmの穴をあけ、 サンブルを 20 u 1づっこの穴に添加し、 37'Cで 1 2 時間放置する。 P A活性が存在すると、 白衝した寒天層は透明になった溶解円が 認められるようになる。 この溶解円の直径を測定し、 ブロウ口キナーゼの標準品 との比較により P A活性を測定する。
After adding 50 parts of 100 U / m1 human thrombin to 1% agar solution of 6 O'C, 50 mM sodium phosphate buffer (PH7.0), 100 mM NaCl, 0. the solution of 37'C which was dissolved 1 ¾ Ushifuiburino one Gen in 1 ¾NaN 3 were mixed in equal amounts was added to a horizontal plate, to solidify the agar. Drill a hole of 4 mm in diameter in the solidified cloudy agar layer, add 20 μl of sample to each hole, and leave at 37'C for 12 hours. In the presence of PA activity, the transparent agar layer becomes transparent with a dissolved circle. The diameter of the lysis circle is measured, and the PA activity is measured by comparison with a standard Blow-mouth kinase.
配列表 Sequence listing
配列番号: 1 SEQ ID NO: 1
配列の長さ : 5 4 Array length: 5 4
配列の型:核酸 Sequence type: nucleic acid
鎖の数:一本鎖 Number of chains: single strand
トポロジー :直欲状 Topology: Direct desire
配列の種類: genomic DNA Sequence type: genomic DNA
mm mm
ブラスミ ド J UK 1 Brasmid J UK 1
配列の特徵 Array features
1-54 S sig peptide 1-54 S sig peptide
配列 Array
ATG TTG TTC TCT AAG ATC TCC TCT GAT ATC TTG TTG ACC GCT GCA AGC 48 Met Leu Phe Ser Lys l ie Ser Ser Ala lie Leu Leu Thr Ala Ala Ser ATG TTG TTC TCT AAG ATC TCC TCT GAT ATC TTG TTG ACC GCT GCA AGC 48 Met Leu Phe Ser Lys lie Ser Ser Ala lie Leu Leu Thr Ala Ala Ser
5 10 15 5 10 15
TTC GCG 54 Phe Ala TTC GCG 54 Phe Ala
18 配列番号: 2 18 SEQ ID NO: 2
^列の長さ : 7 2 ^ Column length: 7 2
配列の型:核酸 Sequence type: nucleic acid
鎮の数:一本鎮 Number of towns: one town
トポロジー:直鎮状 Topology: direct letter
列の種類: Column type:
起源 Origin
PK0113または ρΚΟΙ PK0113 or ρΚΟΙ
配列の特徴
7-60 E sig peptide Array features 7-60 E sig peptide
61-72 E peptide 61-72 E peptide
配列 Array
CTCGAG ATG TTG TTC TCT AAG ATC TCC TCT GCA ATC TTG TTG ACC GCT 48 Met Leu Phe Ser Lys lie Ser Ser Ala He Leu Leu Thr Ala CTCGAG ATG TTG TTC TCT AAG ATC TCC TCT GCA ATC TTG TTG ACC GCT 48 Met Leu Phe Ser Lys lie Ser Ser Ala He Leu Leu Thr Ala
-15 -10 -5 -15 -10 -5
GCA AGC TTC GCG AGC AAT GAG CTC 72 Ala Ser Phe Ala Ser Asn Glu Leu GCA AGC TTC GCG AGC AAT GAG CTC 72 Ala Ser Phe Ala Ser Asn Glu Leu
1
1
Claims
1 . 宿主細胞由来のプロテア一ゼで低分子化され得る蛋白質を分泌産生する宿 主細胞を酸性アミノ酸、 塩基性アミノ酸、 リン酸塩、 アンモニゥム塩および非ィ オン性界面活性剤からなる群から選択される少なくとも 1種を含有する培地中で 培養し、 得られる培養上淸から該蛋白質を採取することを含む宿主細胞由来のブ 口テア一ゼで低分子化され得る蛋白質の製造方法。 1. Host cells that secrete and produce proteins that can be degraded by host cell-derived protease are selected from the group consisting of acidic amino acids, basic amino acids, phosphates, ammonium salts, and nonionic surfactants A method for producing a protein that can be reduced in molecular weight by a host cell-derived porcine protease, comprising culturing the culture in a medium containing at least one of the above-mentioned cultures and collecting the protein from the resulting culture.
2 . アミノ酸がアルギニン、 リジン、 グルタミン酸およびァスパラギン酸から なる群から選択される少なくとも 1つである請求項 1に記載の方法。 2. The method according to claim 1, wherein the amino acid is at least one selected from the group consisting of arginine, lysine, glutamic acid and aspartic acid.
3 . 非イオン性界面活性剤が、 ポリオキシエチレンモノ p— t e r t -ォクチ ルフユニルエーテルおよびポリォキシェチレンソルビ夕ン脂肪酸エステルからな る群より選択される少なくとも 1つである請求項 1に記載の方法。 3. The nonionic surfactant according to claim 1, wherein the nonionic surfactant is at least one selected from the group consisting of polyoxyethylene mono-p-tert-octylfurunyl ether and polyoxetylene sorbin fatty acid ester. The described method.
4 . 非イオン性界面活性剤が、 ポリオキシエチレン (9〜10) モノ p— tert— ォクチルフヱニルエーテル、 ボリォキシエチレン (9 ) モノ ρ— t e r t—ォク チルフヱニルエーテル、 ポリオキシエチレン (2 0 ) ソルビタンモノラウレート およびポリオキシエチレン (2 0 ) ソルビ夕ンモノォレエ一トからなる群から選 択される少なくとも 1つである請求項 3に記載の方法。 4. The nonionic surfactant is polyoxyethylene (9 to 10) mono p-tert-octyl phenyl ether, boroxy ethylene (9) mono ρ-tert-octyl phenyl ether, 4. The method according to claim 3, which is at least one selected from the group consisting of polyoxyethylene (20) sorbitan monolaurate and polyoxyethylene (20) sorbitan monooleate.
5 . 宿主細胞がピキア酵母である請求項 1〜 4のいずれか 1項に記載の方法。 5. The method according to any one of claims 1 to 4, wherein the host cell is Pichia yeast.
6 . 宿主細胞由来のプロテア一ゼで低分子化され得る蛋白質が、 ブロウロキナ ーゼ、 ヒト組織ブラスミノーゲン活性化 Ξ子、 血液凝固第 IX因子、 血液凝固第 X 因子、 プロテイン(:、 インターフェロン、 ェビダ一マルグロースファクター、 β ーェンドルフィンおよびそれらの変異体または誘導体からなる群から選択される ものである請求項 1〜 5のいずれか 1項に記載の方法。 6. Proteins that can be degraded by host cell-derived proteinases include blourokinase, human tissue plasminogen activator, blood coagulation factor IX, blood coagulation factor X, and protein (:, interferon, evida). The method according to any one of claims 1 to 5, wherein the method is selected from the group consisting of one malgrowth factor, β-endolphin, and a mutant or derivative thereof.
7 . 培地が、 (a) 酸性アミノ酸および塩基性アミノ酸からなる群より選ばれる 少なくとも 1つ、 ) リン酸塩およびアンモニア塩からなる群より選ばれる少な くとも 1つ、 および (c) 非イオン性界面活性剤を含有する請求項 1に記載の方法。 7. The medium is (a) at least one selected from the group consisting of acidic amino acids and basic amino acids;) at least one selected from the group consisting of phosphates and ammonium salts; and (c) nonionic The method according to claim 1, further comprising a surfactant.
8 . 培養上清から該蛋白質を採取する方法が、 アンモニゥム塩を含有する緩衝 液を用レ、て培養上淸をカラムクロマトグラフィーで処理することを含む請求項 1 〜 7のいずれか 1項に記載の方法。
8. The method according to any one of claims 1 to 7, wherein the method of collecting the protein from the culture supernatant comprises treating the culture supernatant by column chromatography using a buffer solution containing ammonium salt. The described method.
9. カラムクロマトグラフィーでの処理が、 少なくとも疎水性カラムクロマト グラフィ一での処理および! ¾ィォン交換力ラムクロマトグラフィ一での処理を含 む請求項 8に記載の方法。 9. Column chromatography requires at least hydrophobic column chromatography! 9. The method according to claim 8, comprising a treatment with Zion exchange force ram chromatography.
1 0. ブロウ口キナーゼを分泌産生するピキア酵母をアルギニン、 リン酸アン モニゥムおよびポリオキシエチレン (9〜1 0) モノ p— t e r t—才クチルフ ェニルエーテルを含有する培地中で培養し、 得られる培養上清からブロウロキナ ーゼを採取することを含むブロウ口キナーゼの製造方法。 10. Pichia yeast secreting and producing blow-mouth kinase is cultured in a medium containing arginine, ammonium phosphate and polyoxyethylene (9-10) mono-p-tert-butyl octylphenyl ether, and the resulting culture is obtained. A method for producing blow-mouth kinase, comprising collecting brourokinase from a supernatant.
1 1. 培養上清からブロウ口キナーゼを採取する方法が、 アンモニゥ厶塩を含 有する緩衝液を用レ、て培養上清をカラムクロマトグラフィーで処理することを含 む請求項 1 0に記載の方法。 11. The method according to claim 10, wherein the method for collecting blow-mouth kinase from the culture supernatant comprises treating the culture supernatant by column chromatography using a buffer solution containing ammonium salt. Method.
1 2. カラムクロマトグラフィーでの処理が、 少なくとも睐水性カラムクロマ トグラフィ一での処理および陽イオン交換カラムクロマトグラフィ一での処理を 含む請求項 1 1に記載の方法。 12. The method according to claim 11, wherein the treatment by column chromatography includes at least treatment by aqueous column chromatography and treatment by cation exchange column chromatography.
1 3. ブロウ口キナーゼを分泌産生するピキア酵母。
1 3. Pichia yeast secreting and producing blow mouth kinase.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP6/186602 | 1994-07-14 | ||
JP6186602A JPH0823995A (en) | 1994-07-14 | 1994-07-14 | Production of protein degradable by protease derived from host cell |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996002661A1 true WO1996002661A1 (en) | 1996-02-01 |
Family
ID=16191440
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1995/001399 WO1996002661A1 (en) | 1994-07-14 | 1995-07-13 | Process for producing protein capable of molecular weight reduction caused by protease of host-cell origin |
Country Status (2)
Country | Link |
---|---|
JP (1) | JPH0823995A (en) |
WO (1) | WO1996002661A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6309864B1 (en) | 1997-04-03 | 2001-10-30 | Yoshitomi Pharmaceutical Industries, Ltd. | Process for producing foreign proteins |
US10765245B2 (en) | 2009-07-14 | 2020-09-08 | Belgravia Wood Limited | Power pole for artificial tree apparatus with axial electrical connectors |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2905342A4 (en) * | 2012-10-03 | 2016-03-16 | Kyowa Hakko Kirin Co Ltd | Method for preventing polypeptide reduction by adding amino acid to liquid culture medium |
JP7050528B2 (en) * | 2017-03-01 | 2022-04-08 | 三洋化成工業株式会社 | Production method of useful substances |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63296689A (en) * | 1987-04-15 | 1988-12-02 | ノバルティス アクチェンゲゼルシャフト | Urokinase type plasminogen activating factor and its production |
JPH02104292A (en) * | 1988-04-25 | 1990-04-17 | Phillips Petroleum Co | Manifestation of human interleukin-2 in methyltroph yeast |
JPH05260986A (en) * | 1992-03-16 | 1993-10-12 | Green Cross Corp:The | Method for suppressing coloration of human serum albumin |
-
1994
- 1994-07-14 JP JP6186602A patent/JPH0823995A/en active Pending
-
1995
- 1995-07-13 WO PCT/JP1995/001399 patent/WO1996002661A1/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63296689A (en) * | 1987-04-15 | 1988-12-02 | ノバルティス アクチェンゲゼルシャフト | Urokinase type plasminogen activating factor and its production |
JPH02104292A (en) * | 1988-04-25 | 1990-04-17 | Phillips Petroleum Co | Manifestation of human interleukin-2 in methyltroph yeast |
JPH05260986A (en) * | 1992-03-16 | 1993-10-12 | Green Cross Corp:The | Method for suppressing coloration of human serum albumin |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6309864B1 (en) | 1997-04-03 | 2001-10-30 | Yoshitomi Pharmaceutical Industries, Ltd. | Process for producing foreign proteins |
US10765245B2 (en) | 2009-07-14 | 2020-09-08 | Belgravia Wood Limited | Power pole for artificial tree apparatus with axial electrical connectors |
Also Published As
Publication number | Publication date |
---|---|
JPH0823995A (en) | 1996-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100443307B1 (en) | Expression of Lactoferrin and Lactoferrin Polypeptide Fragments Processed from Fusion Proteins in Aspergillus | |
JP2584186B2 (en) | Gene encoding endoglucanase | |
CA1338642C (en) | Bacterial methionine n-terminal peptidase | |
EP1975237B1 (en) | Beta-fructofuranosidase variants and uses thereof | |
JPH08507695A (en) | EG III Cellulase Purification and Molecular Cloning | |
JPH0789952B2 (en) | Method for enzymatically cleaving recombinant protein with IgA protease | |
NZ218305A (en) | Modified human t-pa, corresponding recombinant dna, vectors and recombinant processes | |
KR101348530B1 (en) | Expression in filamentous fungi of protease inhibitors and variants thereof | |
EP1809741A1 (en) | Endo-n-acetyl-beta-d-glucosaminidase enzymes of filamentous fungi | |
Sørensen et al. | pH‐dependent processing of yeast procarboxypeptidase Y by proteinase A in vivo and in vitro | |
HU212767B (en) | One-step process for producing 7-aminocephem compound or salts thereof, expression vector and microorganism for this purpose | |
Pang et al. | Active expression of human hyaluronidase PH20 and characterization of its hydrolysis pattern | |
KR101367348B1 (en) | Recombinant vector comprising chimeric beta-agarase-B, transformant comprising the same and use of the same | |
WO1996002661A1 (en) | Process for producing protein capable of molecular weight reduction caused by protease of host-cell origin | |
Olędzka et al. | High-level expression, secretion, and purification of the thermostable aqualysin I from Thermus aquaticus YT-1 in Pichia pastoris | |
AU640405B2 (en) | Fungal expression system | |
CA1341306C (en) | Yeast expression of urokinase-type plasminogen activator and mutants thereof | |
Okazaki et al. | Purification and properties of two chitinases from Streptomyces sp. J-13-3 | |
WO2006054595A1 (en) | Novel high alkaline protease and use thereof | |
JP3005621B2 (en) | Ricintoxin | |
Seo et al. | Characterization of a Bifidobacterium longum BORI dipeptidase belonging to the U34 family | |
JP5167813B2 (en) | Protein production method | |
CN112912504B (en) | Maltotriose-producing amylase | |
Konno et al. | An extracellular α‐l‐arabinofuranosidase secreted from cell suspension cultures of carrot | |
US20240229059A9 (en) | Production of recombinant human a-thrombin in plant-based system and the application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA CN KR US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |